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Protein arginine deiminases (PADs) are a class of Ca2+ dependent cysteine 
hydrolases that catalyze a protein post-translational modification known as 
citrullination, where a positive protein-bound arginine residue is converted into a 
neutral unconventional citrulline residue. The reaction results in a shift of protein 
charge from positive to neutral, which dramatically impacts the structure, 
conformation, and function of proteins as well as intra/intermolecular interactions. 
Citrullination represents an important regulatory mechanism affecting several 
physiological cellular processes, such as gene expression, cell differentiation, 
apoptosis, and inflammatory immune responses.  
Among the PAD family members, PAD2 and PAD4, which are the only isoforms 
expressed by immune cells, have attracted considerable interest due to their role in 
producing neutrophil extracellular traps (NETs) and playing a detrimental role in a 
wide range of diseases such as Rheumatoid Arthritis, Ulcerative Colitis, Systemic 
Lupus Erythematosus, Multiple Sclerosis, and Alzheimer's Disease. 
Pharmacological PAD inhibition has brought beneficial therapeutic results in 
animal models of these pathologies since it leads to an amelioration of the disease-
dependent inflammation and reduces immune cell accumulation and tissue damage. 
However, how PAD2 and PAD4 isoforms directly affect immune cell trafficking in 
the context of inflammation has not yet been studied. Hence, this project 
investigated the role of PAD-dependent citrullination in leukocyte adhesive activity 
under physiological and pathological conditions.  
We first treated neutrophils and lymphocytes with different concentrations of BB-
Cl-amidine, a pan PAD inhibitor, and GSK199, which induces PAD4 specific 
blockade, and we studied the effect of cell treatment on b2- integrin-dependent 
adhesion. Our data showed that PAD inhibitors reduce integrin activation and 
binding to endothelial ligands upon stimulation in vitro with chemokines, 
suggesting a role for PADs in rapid leukocyte adhesion mediated by b2 integrins. 
In addition,, we demonstrated that BB-Cl-amidine also blocked lymphocyte b1-
integrin-dependent adhesion on VCAM-1 counterligand, suggesting that PADs are 
involved in controlling signaling pathways common to both b2 and b1 integrin 




confirmed the data obtained with the pharmacological approach and showed that 
mRNA silencing of PADs blocks integrin-dependent adhesion in vitro, further 
confirming the involvement of PADs in leukocyte adhesion. To characterize more 
in detail the role of PADs in adhesion induction, we studied LFA-1 conformational 
changes triggered by chemoattractants and found that treatment with BB-Cl-
amidine and GSK-199 completely prevented integrin transition to more extended 
conformations, suggesting a role for PADs in integrin affinity increase leading to 
leukocyte adhesion.  
Considering the function of PAD2 and PAD4 in NET release and our previous data 
demonstrating a role for neutrophils in animal models of Alzheimer's disease, we 
next investigated the effect of PAD blockade in 3xTg-AD mice, which develop both 
amyloid and tau pathologies. We treated the 3xTg-AD mice with BB-Cl-amidine, 
and the results from behavioural tests showed that PAD inhibition significantly 
rescues spatial working memory and associative learning compared to untreated 
control mice. Histopathological analysis confirmed the beneficial effects of PAD 
inhibitors since microglial activation, amyloid accumulation, and tau 
phosphorylation were strongly reduced after PAD blockade. Finally, we quantified 
brain-infiltrating leukocytes in BB-Cl-amidine treated mice, reporting that treated 
animals show reduced accumulation of neutrophils, CD4+ cells, and B lymphocytes 
compared to untreated mice, suggesting a role for PADs in leukocyte trafficking 
into the brain in AD mice. 
In conclusion, this PhD project demonstrated that PAD2 and PAD4 are key 
elements controlling leukocyte adhesion and that PAD-dependent citrullination is 
required for integrin-mediated adhesion under physiological and pathological 
conditions. Moreover, we reported that PADs are involved in  disease pathogenesis 
in 3xTg-AD mice and that therapeutic blockade of PADs ameliorates cognition and 
reduces neuropathology, suggesting that PAD inhibitors may offer a novel 
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1. PROTEIN ARGININE DEIMINASES 
Protein arginine deiminases (PADs) represent a protein family of cysteine 
hydrolases that catalyses the protein post-translational modification (PTM) known 
as deimination. Citrullination is also used to identify the same reaction, which 
converts a positively charged arginine residue into a neutrally charged citrulline 
residue upon increasing Ca2+ influx. Consequently, the protein charge shifts from 
positive to neutral, a chemical modification that affects protein-protein interactions, 
hydrogen bond formation, protein structure, and protein denaturation[1]. 
The enzymatic activity of PADs was first identified in hair follicle extracts in 
1977[2] but, nowadays, five different isoforms have been described in mammals: 1, 
2,  3, 4 and 6. PAD5 was initially discovered in murine, but it was classified as 
PAD4 since it was recognised as an orthologue of human PAD4.  
Mammalian PADI genes shares a homology of ~ 41-55% and are co-localized on 
chromosome 1 in humans and on chromosome 4 in mice [3]. PAD proteins are 663–
665 amino acids long with a molecular mass of ~ 74 kDa, excluding PAD6 isoform, 
which has 694 amino acids in its sequence[4]. PADs are characterized by two 
immunoglobulin‐like subdomains at the amino‐terminus (from Met1 to Pro300) 
that contain three calcium ion‐binding sites, and by a highly conserved carboxy‐
terminal domain (amino acid 301 to C‐terminus), which includes the catalytic site 
located near two calcium ion‐binding residues (Fig. 1). One histidine, two aspartic 





The N-terminal domain of PAD4 contains a canonical nuclear localization sequence 
[56-PPAKKKST-63], which partially localizes it to the nucleus[6]. Interestingly, 
although the PAD2 enzyme lost this localization signal, it can also localize to the 
nucleus[7]. 
Several mammalian tissues specifically express PADs: the isoforms 1 and 3 are 
found in skin and hair follicles; PAD6 is located in oocytes and embryos, while 
PAD2 and PAD4 are predominantly present in immune cells. However, PAD2 is 
also expressed in skeletal muscle, peripheral nerves, and central nervous system 
(CNS), where it co-localizes with PAD4[1].  
Fig. 1. PAD crystal structure. 
(a-d) Rainbow colour representation of human PADs. Blue and red indicate N terminal 
and C-terminal domains, respectively.  
a) PAD1 monomeric protein. 
b-d) Heterodimeric PAD2 (b), PAD3 (c) and PAD4 (d) 










1. 2. ENZYMATIC ACTIVITY REGULATION  
Ca2+ ions regulate the catalytic function of PADs, inducing protein conformational 
changes that collocate the catalytic cysteine in the right position for the catalysis, 
as illustrated in Fig. 2[8].  
 
Indeed, after Ca2+ binding, cysteine could react with the guanidine group of the 
arginine substrate since it is located closer to it, forming a covalent tetrahedral 
intermediate associated with ammonia release (Fig. 3).  
  
Ca2+ 
Fig. 2. Ca2+ dependent PAD structural change. 
Backbone conformational changes of PAD2. The catalytic domain is shown in green, and 
the cysteine residue in red. The immunoglobulin-like subdomains 1 and 2 are shown in 
pink and blue, respectively. 
From V. V. Nemmara and P. R. Thompson, Curr Top Microbiol Immunol, 2019. 
Fig. 3. The chemical reaction of citrullination. 
The hydrolysis of arginine to citrulline. PADs catalyze the nucleophilic attack of the 
primary arginine ketimine group, resulting in the formation of a ketone group and 
ammonia release. 





Then, the adduct is hydrolyzed, releasing the cysteine and forming a keto‐group. 
PAD4 binds five Ca2+ ions in an ordered fashion, as well as PAD2. Analogously, 
PAD1 has four calcium-binding sites[9]. PADs require high micromolar amounts of 
Ca2+ (1-10mM), not always available in the intracellular environment. Therefore, 
other factors are supposed to control the enzymatic activity. In vitro biochemical 
studies have recently demonstrated that physiological levels of bicarbonate 
upregulate citrullination in neutrophils, independently of calcium concentration and 
pH value[10]. A redox intracellular environment is also important for PAD catalysis 
since the chemical reduction of the active site allows the cysteine attack on the 
targeted guanidinium group. The physiological redox agents, which may be 
responsible for PAD reduced state, are the glutathione reductase, physiologically 
implicated in the protection against ROS and RNS[11], and the thioredoxin 
oxidoreductase, involved in maintaining tissue redox homeostasis[12]. It may be 
concluded that citrullination is regulated by an equilibrium of multiple factors. 
Interestingly, PADs are also able to control themselves through auto-deimination, 
which showed controversial effects. It seems that two arginines directly involved 
in substrate recognition could be auto-citrullinated, resulting in 3D structure 
changes and enzymatic activation. Alternatively, the auto-deimination of the 
substrate recognition site does not induce total protein conformational changes, but 
a slight movement of the active site that blocks PAD activity[13, 14]. 
 
1. 3. CITRULLINATION 
Post-translation modifications (PTM) are a complex regulatory mechanism of 
protein function, impacting charge state, hydrophobicity, conformation, and 
stability. Therefore, they affect processes such as signaling, localization, and 
protein degradation. To date, more than 450 PTMs have been identified, including 
phosphorylation, acetylation, ubiquitination, SUMOylation, and citrullination[15].  
Citrullination is catalyzed by the PAD family, which converts, in the presence of 
Ca2+ ions, the peptidyl arginine residue into citrulline residue. Since it leads to just 




challenging. The protein electrostatic change, from positive to neutral, is the most 
critical effect of citrullination, affecting protein folding, hydrophobicity, and intra- 
or inter-molecular interactions[16]. Although all the PTMs are reversible, an enzyme 
able to convert citrulline into arginine has not yet been discovered [17].  
Another feature of PTMs is their reciprocal crosstalk, an additional regulatory 
mechanism of protein function. Recently, it has been shown a negative mutual 
interaction between PAD2-mediated histone H3R26 citrullination and EZH2-
mediated H3K27 methylation, which seems to complicate the epigenetic 
background. In particular, citrullination on R26 completely blocks methylation on 
K27, which in turn decelerates citrullination on R26. The fact that citrullination 
abrogates EZH2 activity may be explained by the fact that, once histone is 
citrullinated, its folding is dramatically compromised leading to hide the 
methyltransferase interaction. On the contrary, methylation induces only a 30-fold 
reduction of PAD2 catalytic efficiency[18]. 
Even if citrullination is one of the less studied PTMs, it has been found that this 
natural reaction is physiologically involved in several processes and has a negative 
role in pathologies such as chronic inflammation, immune disorders, 
neurodegenerative diseases, skin-related pathologies, and infertility[19].  
 
1. 4. PAD PHYSIOLOGICAL FUNCTIONS 
1. 4. 1. PAD2 
PAD2 is the most conserved homologue of the mammalian ancestral PADs[20]. It is 
widely expressed in oligodendrocytes, immune cells, granular keratinocytes, and 
skeletal muscle cells[4, 21, 22].  
PAD2 can be transported into the nucleus in response to calcium signaling, even 
though it lacks the nuclear localization sequence, still present in PAD4 isoform. 
Indeed, a calcium-dependent phospholipid-binding protein, known as annexin A5, 
associates with the cytoplasmatic PAD2, preventing its translocation into the 
nucleus. Upon Ca2+ influx increase, PAD2 releases annexin A5 and interacts with a 




Nuclear PAD2 citrullinates histone 3 and histone 4 substrates that had been 
previously considered exclusive targets of PAD4, mediating chromatin 
decondensation and inducing neutrophil extracellular traps (NETs). NETosis is a 
pro-inflammatory form of cell death, which eliminates invading pathogens and 
restores homeostasis. Inflammatory stimuli, such as LPS, PMA or IL-8, stimulate 
neutrophils to release DNA web-like structures, citrullinated histones, and primary 
(NE, cathepsin G, MPO) and secondary/tertiary (lactoferrin, gelatinase) granular 
proteins[23]. The exact implication of PAD2 in NETosis is not clearly understood. 
Previous studies suggested that PAD4 is the main citrullinating enzyme whereas 
PAD2 represents a dispensable enzyme[24]. However, other reports demonstrated 
that NET citrullination does not require PAD4, but nuclear PAD2[25]. A possible 
explanation of these controversial data is that NET release is mediated by several 
stimuli, which activate different PADs. For example, PAD4 does not respond 
to Klebsiella pneumoniae or C. albicans stimuli, while PAD2 is not required 
TNFa or LPS induced NETs[26].  
In addition to neutrophils, it has been recently reported that other immune cells 
release decondensed chromatin fibers similar to NETs, which are generally referred 
to as ETs (Extracellular Traps). Macrophage ETs, called METs, depend on 
citrullinated histone 3 and histone 4 as neutrophils. Unlike NETs, preliminary 
findings demonstrate that during MET formation, PAD2 is the main enzyme 
required for histone citrullination [27]. 
Recently, it has been found that activated CD4+ T cells release DNA extrusions, 
called T helper-released extracellular DNA (THRED). In line with previously 
described ETs, THREDs contain nuclear DNA and citrullinated histones, which 
have already show a detrimental role in T-cell-mediated autoimmune disorders[28].  
Apart from its relatively recent established role in ETosis, PAD2 is also involved 
in macrophage and lymphocyte apoptosis, a pathway dependent on the transient 
increase of the cytosolic Ca2+ concentration, which leads to PAD2 activation[29]. 
The enzyme deiminates the N-terminal domain of vimentin, an intermediate 
filament associated with the support and anchorage of cytosolic organelles[30]. 
Protein citrullination mediates vimentin disassemble, affecting cell cytoskeleton 




keratinocytes express PAD2 isoform, which is supposed to cooperate with PAD1 
in the cornified envelope protein deimination[4].  
Moreover, PAD2 is present in oligodendrocytes (OLs), where it participates in cell 
differentiation through histone 2 citrullination and epigenetic gene transcription 
regulation.  
 
Once OLs are differentiated, PAD2 regulates the myelination process, directly  
targeting myelin component proteins, which is considered a physiological event 
that contributes to normal myelination and motor function. Indeed, PAD2 lacking 
mice show motor and cognitive defects[32]. PAD2-mediated differentiation and 
myelination of OLs are represented in Fig. 4. 
Autoimmune and allergic reactions are also regulated by PAD2-mediated 





Fig. 4. PAD2 mediates differentiation and myelination of OLs. 
Graphical illustration of PAD2 role in CNS. The isoform 2, localized within the nucleus, 
contributes to the epigenetic transcription of OL differentiation genes. Cytoplasmatic 
PAD2 citrullinates myelin component protein, leading to myelination and motor 
function. 






When PAD2 citrullinates the R330 of GATA3, a key transcription factor (TF) for 
T helper 2 (Th2) cells, its DNA binding ability decreases, whereas citrullination of 
RORgt, the most important TF for Th17 subsets, has the opposite effect[33]. The 
double regulation of Th subsets implies that PAD2 blocking may be advantageous 
in Th17 cell-mediated inflammation, such as arthritis or colitis, but could worsen 
Th2 cell-mediated diseases, such as allergic inflammation. 
Although PAD2 was first isolated in skeletal muscle, its relative function has not 
yet been clarified, probably due to very low levels of citrullinated proteins[34]. 
 
1. 4. 2. PAD4 
PAD4 is the best characterized isoform among the PAD family. It is the main 
protein responsible for nuclear citrullination since it is the only PAD to retain the 
canonical nuclear localization sequence. Its expression is restricted to immune cells, 
where it is involved in inflammation, gene expression, and cellular differentiation. 
PAD4 is even localized in CNS, especially in neurons and myelin sheath, but it has 
been described as inactive[35]. Neutrophils represent the major source of isoform 4, 
Fig. 5. PAD2 regulates Th2/Th17 cell response. 
PAD2-mediated citrullination inhibits Th2 and enhances Th17 cell differentiation. 
Citrullination of GATA3 reduces its DNA binding affinity, while deimination of RORgt 
increases Th17 gene transcription. 
The epigenetic modulation of Th2/Th17 responses may represent a novel therapeutic 
strategy for Th17 cell-mediated inflammation, but it could exacerbate Th2 cell–mediated 
allergic inflammation. 





where it is crucial for NETosis and neutrophil oxidative burst. NET formation starts 
with cell polarization and proceeds with nuclear envelope disassembly and 
chromatin decondensation; next, granule proteins are released in the cytosolic 
environment, plasma membrane permeabilizes, and web-like structures appear in 
the extracellular space within 3–8 hours[36]. In this complex pathway (shown in Fig. 
6), PAD4 activated by pro-inflammatory stimuli and by increases in both ROS and 
Ca2+ levels, moves into the nucleus where it neutralizes the positive arginine charge 
of histones, decreasing histone electrostatic interactions and histone/DNA 
attraction. Thus, DNA, which is tightly linked to histones to form the chromatin 
structure, starts to unravel[37]. As mentioned in the previous paragraph, it is now 
established that other immune cells release chromatin traps such as macrophages, 
which predominately require PAD2 catalytic activity[27], and lymphocytes, where 
the exact role of PADs has not yet been clarified, although citrullinated histones 
and chromatin decondensation occur[28]. Recently, it has been demonstrated that 
PAD4 regulates the production of neutrophil ROS, which are oxygen species 
indispensable for activation of phagocytosis, killing, and NETosis[38].  
Fig. 6. PAD4 mediates histone citrullination and induces chromatin decondensation. 
Neutrophils release web-like structures during NETosis, starting from nuclear delobulation 
and envelope disassembly. Intracellular Ca2+ influx activates nuclear PAD4, which 
citrullinates chromatin-linked histones. Electrostatic interactions between histones and DNA 
decrease. Finally, plasma membrane permeabilizes and decondensed chromatin is extruded. 
The image was adapted from Venizelos Papayannopoulos, Nat Rev Immunol, 2018. Lower 




Compared to other immune cells, neutrophils have fewer mitochondria and use the 
NADPH oxidase complex to produce ROS. PAD4 acts as structural anchorage to 
stabilize cytosolic subunits of NADPH burst machinery, named neutrophil cytosol 
factor (NCF) 1 and 2, but this association does not require citrullination. Indeed, it 
dissociates under membranolytic agent insults, such as perforin or Membrane 
Attack Complex (MAC), as a consequence of lethal calcium influx and PAD4 
hyperactivation, which results in deimination of NCF1 and NCF2 and in impairing 
ROS production. During physiological neutrophil activation, PAD4 remains 
associated with NADPH subunits, avoiding their disaggregation. Moreover, in the 
same context, other cytosolic PAD4 molecules can enter the nucleus and citrullinate 
histones, leading to NETosis[39]. Apart from its inflammation-related role, PAD4 
induces cell death through the citrullination of nucleophosmin. This nucleolar 
protein inhibits p53 translocation to mitochondria, a canonical key step in 
apoptosis. Once citrullinated, nucleophosmin changes its folding and binds p53, 
facilitating its localization inside the mitochondria[40, 41]. In addition, nuclear PAD4 
acts as a transcription factor, regulating gene expression. For example, PAD4 can 
upregulate pluripotent markers (Klf2, Tcl1, Tcfap2c, Kit, Nanog) or downregulate 
differentiation markers (Prickle1, Epha1, Wnt8a)[42]. Moreover, PAD4 targets p53 
promoter leading to its gene silencing. However, in cases of heavy DNA injury, 
PAD4 dissociates from the promoter and induces transcriptional activation of the 
DNA repair pathway[43].  
 
1. 4. 3. OTHER PADs 
PAD1 is expressed in the intracellular filamentous matrix of corneocytes and in the 
cytoplasm of keratinocytes, where it is involved in the epidermal differentiation. 
During their differentiation, keratinocytes move from the basal to the upper layer 
of the epidermis (stratum corneum), undergoing structural and metabolic changes, 
resulting in corneocyte cell maturation. PAD1 is present mainly in the stratum 
corneum, and it is requested in keratinocyte to corneocyte transition through 







Keratins and filaggrin have a high-affinity binding, resulting in the formation of an 
insoluble complex of lower corneum stratum, which contributes to the compaction 
of squames and stratum integrity. The lifetime of this structural component is rather 
short since it is disrupted during transition to upper corneum stratum. Citrullination 
of these substrates facilitates their dissolution and the enzymatic attack of 
transglutaminases 1 and 3, which finally cross-link keratin to other citrullinated 
Fig. 7. Illustration of PAD1 distribution in epidermal layers and effects of 
citrullination on filaggrin and keratins. 
On the left panel, PAD1 distribution is represented by its isoform number. All the 
epidermal layers are indicated. 
On the right panel, filaggrin (Fil) interacting with keratin intermediate filaments (KIF) in 
the lower corneum stratum. Once filaggrin is deiminated, filaggrin/KIF complex 
dissociates, leading to NMF production and citrullination of keratins. 




proteins, such as hornerin, in order to mediate cornified envelope formation, the 
last step of corneocyte differentiation[44].  
Moreover, once filaggrin is deiminated, it is degraded into free amino acid, forming 
the Natural Moisturizing Factor (NMF), a pool of hygroscopic molecules that 
contribute to the hydration of the upper corneum stratum [4].  
PAD1 activity has also been detected in hair follicles, where it citrullinates 
trichohyalin, a protein responsible for hair morphology. Deiminated trichohyalin 
undergoes structural protein reorganization and interacts with keratin filaments 
offering mechanical support to hair follicle structure and growth[4].  
PAD1 and PAD3 are the evolutionary closest isozymes among the family, with 
68% of identical amino acid sequence in mammals[45]. PAD3 isoform shares with 
PAD1 the hair follicle expression but it also has a unique tissue localization: it is 
the only PAD member present in all the three layers of the inner root sheath (the 
Henle layer, the Huxley layer, and the cuticle) and in the medulla of hair shaft. 
PAD3 targets trichohyalin in the medulla compartment, where citrullinated protein 
forms cross-linked homo-oligomers and vacuolated aggregates, which absorb air 
and, therefore, are essential for thermal insulation. In the inner root sheath, 
deiminated trichohyalin offers mechanical support to the hair follicle structure and 
growth, suggesting that citrullination may have a tissue-, organelle-, and even site- 
dependent effects[46]. 
The isoform 3 is specifically expressed by granular keratinocytes, being located in 
keratohyalin granules and filamentous matrix of lower corneum stratum.  
In these cellular compartments, the isoenzyme cooperates with PAD1 to offer 
enzymatic support. Indeed, keratins and filaggrins are classified as PAD3 
substrates[4].  
PAD3 has been recently found in neuronal stem cells, where it seems to regulate 
cell death via AIF (apoptosis-inducing factor) cleavage dependent, which has been 
shown to requires PAD3 citrullination, or through citrullinated vimentin, a 
structural intermediate filament protein which leads to cytoskeleton integrity 
disruption after deimination [47].   
PAD6 shares only ~ 42 % homology with the rest of the family[48]. Its amino acid 




therefore, PAD6 has been supposed to catalyze citrullination only during 
embryonic development[43]. It is uniquely expressed in mammalian oocytes and pre-
implanted embryos, where it associates with cytoskeletal sheets[49].  
PAD6 is one of the few studied oocyte genes with maternal effects that regulates 
embryonic development at the two-cell stage. Zygotes from female PAD6 
deficient-mice are not able to pass the two-cell stage of development, compared to 
the wild-type zygotes, which progress until 8-16 cell stages. Therefore, PAD6 is 
essential for the regulation of female fertility. Male mice that lose PAD6 protein 
expression are still fertile, confirming the role of PAD6 as maternal genes[49].   
In the oocyte and zygote, PAD6 regulates embryonic gene transcription activation 
crucial for the formation of cytoplasmic lattice structures, which function as 
maternal ribosomes and mRNA storage[50]. Moreover, in the cytoplasmic lattices, 
PAD6 is also a key regulator of organelle positioning and movement, which is 
largely mediated by microtubule. Microtubules are associates with motor proteins 
such as tubulin, which is physically associated with PAD6. Citrullination of this 
fibrous complex induces microtubule polymerization, motor activity, and finally 
organelle positioning[51].  
In germ cells, PAD6 dependent citrullination also mediates the formation of 
cytoskeletal sheets through cytoplasmatic or structural proteins deimination, such 
as keratins, leading finally to a correct embryo development[52]. 
 
1. 5. PATHOLOGICAL ROLES OF PADs 
1. 5. 1. PAD2 AND PAD4   
Studies carried out over the last decade have demonstrated that dysregulation of 
both PAD2 and PAD4 is commonly associated with the pathogenesis of 
neurodegenerative diseases (such as Multiple Sclerosis, Alzheimer's, and 
Parkinson's Diseases)[53-55] and inflammatory and autoimmune disorders (such as 
Ulcerative Colitis, Systemic Lupus Erythematosus, Atherosclerosis, and 
Rheumatoid Arthritis)[56-58]. 




is functional during cerebral development[1]. However, its detrimental activity has 
been previously described in neurodegenerative disorders, such as multiple 
sclerosis (MS), Parkinson’s disease (PD) and Alzheimer’s disease (AD).  
MS is a chronic inflammatory autoimmune demyelinating disease of the CNS, 
characterized by the destruction of myelin sheath around the axon, inflammatory 
and degenerative changes in the brain and spinal cord (SC). In MS, the myelin basic 
protein (MBP), implicated in the maintenance of correct myelin structure and 
axonal impulse conduction, is hypercitrullinated.  
 
Abnormal MBP deimination produces open protein conformation, increasing 
proteolytic susceptibility to cathepsin D protease, which catalyzes myelin 
breakdown (Fig. 8). White matter from MS patients presents hypomethylated 
PADI2 gene promoter compared to healthy patients. This tissue-specific epigenetic 
landscape correlates with brain PADI overexpression and results in an abnormal 
increase in target citrullination[54]. Recently, other substrates, such as GFAP and 
vimentin, have been discovered as hypercitrullinated in the white matter of MS 
patients.  Interestingly, abnormal PAD-mediated deimination has not been 
correlated to CD4+ cell autoreactivity, which might occur in the presence of 
citrulline since it is not available during thymic selection[59]. 
Fig. 8. MBP deimination in MS. 
In healthy individuals, PADI2 promoter has a methylated cytosine residue, epigenetic state 
which decreases protein transcription level. In MS patients, the gene promoter is 
demethylated at cytosine, and it correlates with PAD2 transcription increase. The amount 
of citMBP rises with relative lipid bilayer destabilization and protein degradation. 






PD is a long-term neurodegenerative disorder that affects normal motor functions. 
Indeed, it is characterized by the loss of dopamine neurons in the substantia nigra. 
A correlation between PADs and PD has been previously suggested, considering 
that these enzymes are upregulated in patients, but the driver trigger for this 
alteration has not yet been investigated[55]. The accumulation of neuronal a-
synuclein aggregates in substantia nigra, or in the peripheral nervous system plays 
a central role in PD pathogenesis. These aggregations of aberrant soluble a-
synuclein oligomers are cell toxic and contribute to neuronal and synaptic loss 
[60]. Recently, a-synuclein has been shown as PAD substrate, and its citrullination 
seems to trigger CD4+ cell activation, contributing to detrimental inflammatory 
changes that occur in PD brains[61]. 
AD is the most common form of dementia, contributing to 60-70% of the cases[62]. 
It is characterized by neuronal loss in medial lobe and temporo-parietal association 
cortices by intraneuronal neurofibrillary tangles (NTFs), composed of a 
hyperphosphorylated form of tau protein, and by extracellular β-amyloid peptides 
(Aβ) deposits[63]. Post-mortem histochemical analysis on AD human brains, 
represented in Fig. 9, revealed that hippocampal extracts contained abnormal 
accumulation of citrullinated proteins[53].  
 
Fig. 9. Immunohistochemical qualitative images of citrullinated proteins in 
hippocampal sections. 
(A-B) Human hippocampal regions, CA areas and dentate gyrus, were stained with anti-
modified citrulline antibody. In A, hippocampus of AD brains is shown, where brain 
sections indicate antibody positivity; in B), immunohistochemistry from control brains, 
where no citrullinated proteins at all were identifies.  





This result suggests that PADs become activated in cerebral regions involved in 
AD neurodegeneration and that PAD could play a role in the progression of AD. 
Among citrullinated proteins, GFAP and vimentin, expressed by astrocytes, were 
clearly identified and may provide a positive contribution to AD. Indeed, 
deimination of these intermediate filaments leads to their unfolding and to astrocyte 
size and shape changes, probably enhancing reactive cell phenotype, which occurs 
in order to phagocyte extracellular proteins such as Aβ[64]. Inflammation is another 
pathological hallmark of AD. We have previously demonstrated that, in murine and 
human parenchyma, circulating immune cells adhere in brain vessels, extravasate 
closed to amyloid-b deposits, and, in the case of neutrophils, release NETs [65]. 
PAD2 and PAD4 are essential for NET formation, and citrullinated histones and 
proteases may damage endothelial and neural cells or they may harm the blood-
brain barrier (BBB) integrity, contributing to AD pathogenesis [66].  
Abnormal NET formation is also a hallmark of several inflammatory and 
autoimmune diseases, and the fact that PAD4 and PAD2 are required for web-like 
structure extrusion indicates that PADs are deeply involved in the severity of these 
diseases. 
Ulcerative colitis (UC) is one of the major forms of autoimmune inflammatory 
bowel disease. Its pathogenesis is not entirely understood even though it becomes 
clear that UC is characterized by an abnormal immune response against luminal 
antigens, which correlates with chronic intestinal inflammation. Neutrophils 
damage mucosal areas and release NETs, and therefore, PAD4 is considered one of 
the major players in UC. Indeed, UC patients present higher PAD4 level expression 
compared to controls in the mucosal inflamed area[57]. Recently, PAD4 has been 
proposed as a clinicopathological prognostic predictor in UC since its 
overexpression is significantly associated with histopathologic grade increase and 
anatomical disease extent[67].  
Systemic lupus erythematosus (SLE) is an autoimmune disorder that presents innate 
and adaptive immunity dysregulation. Typical features are systemic clinical 
manifestations, including skin, kidneys, joints, heart and lungs, autoantibodies 
generation, and immune complexes (ICs) reactivity[68]. NET formation/clearance 




inflammasome activation, aberrant adaptive immunity, and tissue damage[35]. In 
genetically prone mouse models of lupus, NZM2328, and MRL/lpr, PAD targeting 
inhibitors abrogate disease phenotype and immune dysregulation. These 
compounds also reduce the lupus-associated vasculopathy and thrombosis[69, 70]. In 
TLR7-mediated SLE mouse model, it has been demonstrated that PAD2 and PAD4 
have different regulatory roles: PAD4 expression abrogation protected mouse from 
antibody production, type I IFN response, renal IC deposition, and endothelial 
dysfunction; while PAD2 seems to be the main regulator of Th1 and Th17 immune 
responses, which have been correlated with lupus-associated nephritis[71]. Human 
studies also support the involvement of PADs in this pathology since specific SLE 
polymorphism (A20) has been associated with increased protein citrullination 
levels[72] and PAD4 polymorphism with the renal involvement[73]. One of the main 
SLE-related PAD targets is LL37, a member of the cathelicidin granular protein 
family, which triggers pathogenic autoantibodies[74]. Abundant citrullination of 
LL37 in human patients causes the loss of T cell immune tolerance, and was 
implicated in SLE autoreactivity[74]. 
Atherosclerosis is a cardiovascular disease where patients are characterized by 
chronic vascular wall inflammation, endothelial dysfunction, and smooth muscle 
cell proliferation. Typical manifestation is the atherosclerotic plaque formation 
associated with hyperlipidemia, which induces neutrophilia[75]. The cholesterol 
crystals of the plaque act as IL-1β production inducer, attracting neutrophils that 
release NETs closed to plaques, where they exert several pro-inflammatory 
functions. Cathepsin G, cathelicidins, or cathelicidin-related antimicrobial peptide 
(CRAMP), which are extruded during NETosis, attract monocyte and dendritic 
cells. Moreover, NETs trigger cytokine production from macrophages and activate 
Th17 cells, enhancing leukocyte infiltration within the plaque[76]. In addition, NETs 
exert cytotoxic and prothrombotic effects and are directly correlated with lesion 
size in atherosclerosis and cardiac infarct[77]. The detrimental contribution of PADs 
is due to their essential role in NET formation: in murine models, PAD 
pharmacological inhibition showed decreased atherosclerotic lesion dimension and 





Rheumatoid Arthritis (RA) is a chronic inflammatory disorder associated with 
severe synovial tissue inflammation and irreversible cartilage and bone damage 
within the joints[79]. Citrullination is a hallmark of RA since it initiates and 
maintains the rheumatic autoimmune reaction and the diagnosis is based on the 
presence of anti-citrullinated protein antibodies (ACPA) in the synovial fluid (SF) 
of RA patients[80]. In RA pathogenesis, hyperactivated PADs may catalyze non-
selective citrullination such fibrinogen, vimentin, enolase, and therefore may 
deiminate not canonical substrates, leading to neo-citrullinated proteins not 
recognized by the immune system as self-antigens and driving an autoimmune 
response[56].  
 Abnormal citrullination levels have been found in intra- and extracellular 
compartments, suggesting that PADs are hyperactivated in both these cell 
environments. In the SF of RA affected individuals, neutrophils are the most 
abundant immune cells and the main source of PAD dysregulation[81].  
It is supposed that neutrophil intracellular hypercitrullination is due to immune 
pore-forming pathways active in the joints, such as perforin and MAC, which 
induce massive Ca2+ ions and hyperactivation of PADs[82]. Extracellular presence 
of deiminated substrates is correlated to an abnormal NETosis, which releases 
PADs that citrullinate extracellular substrates and break immune tolerance. 
Moreover, PAD4 acts itself as an autoantigen in RA and generates a recently 
described subset of RA antibodies known as anti-PAD4 antibodies. These can lower 
the amount of Ca2+ required for the catalysis, establishing continuous active cycles 
of hypercitrullination[83]. These effects of dysregulated citrullination are 





PADs are also involved in numerous malignant tumors by regulating apoptosis and 
differentiation, promoting EMT and metastasis, and tumor-associated 
inflammation[84].  
In cancer cells, PAD2 has been shown to play a protooncogenic role. For instance, 
in gastric cancer, PADI2 facilitates abnormal cancer cell behavior by increasing 
expression levels of CXCR2, a gene correlated to cell proliferation and tumor 
invasion. PADI2 has deleterious effects on tumor growth and metastasis even in 
liver cancer via regulation of tumor growth gene erythropoietin[85].  
PAD4 negatively regulates tumor invasiveness in breast cancer by citrullinating 
glycogen synthase kinase-3β (GSK3β), inducing epithelial to mesenchymal 
transition[40]. Moreover, PADs regulate epigenetic expression of estrogen-
responsive genes, mediating neoplastic growth. Interaction between PAD4 and p53 
leads to the block of apoptotic pathway in a wide range of tumors such as lung 
cancer, osteosarcoma, and hematopoietic cancers[86]. 
Fig. 10. Normal citrullination and RA-associated hypercitrullination. 
In A, PADs are tightly controlled by limited intracellular Ca2+ levels or other hypothesized 
regulating factors. In addition, residue clearance prevents the abnormal intracellular 
citrulline accumulation. In B-C, Bacteria or MAC/perforin induce leukotoxic 
hypercitrullination (LTH). Moreover, bacteria may trigger ACPA production in extra 
articular sites (gut, gums, lungs). The huge amount of died neutrophils represents an 
additional source of hyperactive PADs in intra articular regions.  




In melanoma, breast, colon, kidney, ovarian, lung, and prostate cancers, PAD2 and 
PAD4 have been detected in exosome and extracellular microvesicles (EMV), 
where they deiminate cytoskeletal proteins, such as actin, resulting in structural 
membrane rearrangement that vesicle release needs .Therefore, PADs may 
indirectly contribute to chemo response therapy, which EMV strongly generate by 
carrying drugs within them[84]. 
 
1. 5. 2. OTHER PADs  
Although the role of PAD1 has been thoroughly characterized in the normal 
functionality of keratinocytes, little is known about PAD1-mediated citrullination 
in cutaneous diseases. Indeed, psoriasis vulgaris is the only skin-related disease 
associated with PAD1 deficiency[52]. 
Psoriasis is a chronic inflammatory cutaneous pathology, which causes red and 
scaly patches, localized mainly on knees, elbows, trunk, and scalp. It is 
characterized by an excessive mitotic activity, correlated to hyperproliferation of 
keratinocytes, which move from basal to upper epidermal layers within days, rather 
than months, and accumulate in dry patches[87]. In normal human cornified cells, 
keratin 1 is the most abundant citrulline-containing protein[88]. Lack of keratin 
citrullination in psoriatic lesions has been widely detected, resulting in the atypical 
arrangement of keratin tonofibrils, which compromises epidermal compactation[89]. 
It is not clear whether the uncommon cell proliferation induces abnormal 
deimination or PAD1-decreased citrullination causes the accumulation of 
keratinocytes within the dermis.  
Apart from its role in epidermis related diseases, PAD1 has been recently classified 
as the only PAD family member involved in the pathogenesis of human triple 
negative breast cancer (TNBC), the most aggressive form of breast cancer. It 
correlates with the upregulation of isoform 1 activity, which results in cell 
proliferation, epithelial-mesenchymal transition, and metastasis increase[90]. How 
PAD1 starts to be dysregulated has not been described, but the molecular 




inhibits MEK1-induced ERK phosphorylation, resulting in MMP2 overexpression, 
a metalloproteinase involved in tumor progression through the breakdown of ECM 
components[40]. 
In line with its hair follicle localization, PADI3 mutations are involved in the 
pathogenesis of a rare inherited hair shaft dysplasia, which mostly affects young 
children, known as Uncombable Hair Syndrome (UHS). The disorder presents 
tousled follicles, which do not fat on the scalp, and consequently, patients show dry, 
curly, and shiny hair. PADI3 mutations compromise enzymatic activity, resulting 
in the inhibition of trichohyalin citrullination. This is correlated with a triangular 
and flat form of the hair shaft.  
Different variants of PADI3 are also correlated with central centrifugal cicatricial 
alopecia, a form of inflammatory scarring alopecia, which affects African women. 
The pathology is characterized by hair breakage, perifollicular lymphocyte 
infiltration, and follicular degeneration. Missense mutations lead to decreased 
enzymatic activity, correlated with reduced citrullinated trichohyalin, which is 
supposed to result in follicular degeneration[4].  
Considering that, in granular keratinocytes, isoforms 3 and 1 of PADs cooperate 
for keratin deimination, PAD3 downregulation is obviously associated with 
psoriasis pathomechanism.  
PAD6 is the only PAD member responsible for women's fertility. Homozygous 
PADI6 nonsense mutation in oocytes generates a truncated PAD6 protein, which 
impacts early embryonic arrest. Indeed, PAD6 activity is correlated with oocytes 
cytoplasmic lattice and subcortical maternal complex formation, essential for 
embryonic progression at the 2-cell stage in mice[91].  
Recently, PADI6 biallelic missense variant has been associated with recurrent 
hydatidiform moles (RHM), an aberrant human pregnancy characterized by 
degeneration of chorionic villi and hyperproliferation of the trophoblast. The 
implication of PAD6 in RHM is always due to PAD6 mediated cytoplasmic lattice 
formation. Whereas PADI6 nonsense mutation induces a truncated form of the 
protein, which causes early embryonic  
, the missense variant only delays it, consenting blastocyst implantation, and 




1. 6. PAD INHIBITORS AND THEIR THERAPEUTICAL 
APPLICATIONS 
Considering that citrullination has a critical and potentially irreversible detrimental 
role in several inflammatory and autoimmune disorders, a massive influx of interest 
into PAD activity inhibition is raised in the last decades. The development of 
compounds targeting PADs represents an advancement in the understanding of 
physiological and pathological functions of PADs, providing a novel therapeutic 
strategy for deimination-related disorders. 
In the next paragraphs, the inhibition mechanism and the therapeutic applications 
of PAD2 and PAD4 inhibitors are described since these isoforms are the main 
object of our interest. 
The first bioactive pan PAD inhibitor was discovered in 2006, and it was called 
Fluoro acetamidine (F-amidine), which mimicked the smallest PAD substrate, the 
benzoy-L-arginine amide, in which one of its amino group was replaced with 
methylene fluoride. The resulting compound sterically fits in the active site of the 
enzymes, forming a stable thioether adduct that blocks the nucleophilic attack of 
PADs[93]. 
  
The F-amidine was optimized leading to the production of Cl-amidine, by replacing 
the fluorine with a chlorine residue in the haloacetamidine warhead (Fig. 11).  
Fig. 11. Structures of amidine-based PAD inhibitors. 
Chemical conformation of benzoyl arginine amide (BAA) is displayed on the right panel. 
On the left, the comparison between F-amidine and Cl-amidine. The amino group of the 
canonical substrate is replaced with fluoride (2) or chlorine residue (1). 






The mechanism of irreversible PAD blocking was the same as for the F-amidine 
compound, since Cl-amidine inhibits the calcium bound form of PAD enzymes, but 
with enhanced potency[94]. Cl-amidine demonstrated efficacy in animal models of 
RA, SLE, UC, spinal cord injury, breast cancer, and atherosclerosis. Despite these 
results, the drug showed to have poor metabolic stability and cell membrane 
permeability. In an effort to address these issues, the C-terminal carboxamide was 
replaced with a benzimidazole moiety to yield BB-Cl-amidine (Fig. 12), ten times 
more potent than Cl-amidine both in vitro and in vivo[95]. 
 
 
In order to study single PAD enzyme function, selective isoform inhibitors were 
also developed through screening of DNA-encoded small-molecule libraries, with 
and without added Ca2+. 
 GSK121 was the first PAD4 selective inhibitor, which demonstrated high affinity 
to the calcium-free form of the isoform. Optimization of GSK121 led to GSK199, 
which reversibly binds the low-calcium associated conformation of the enzyme 
(Fig. 13). 
 
Fig. 12. Chemical structure of BB-Cl-amidine. 
BB-Cl-amidine is a C-terminal bioisostere of Cl-amidine. The C-terminus of Cl-amidine is 
replaced by a benzimidazole group and the N-terminus with biphenyl moiety to increase 
hydrophobicity and cellular uptake. 





GSK199/PAD4 complex prevents the substrate from reacting with the catalytic site 
in a typical competitive mechanism of inhibition, demonstrating a strong inhibitor 
effect on the citrullination of PAD4 targets and NET formation in both human and 
murine neutrophils[96].  
Considering the detrimental role of PAD2 and PAD4 in the pathogenesis of 
inflammatory and autoimmune diseases, several applications of the above-
mentioned inhibitors were performed to investigate their effects in the field of target 
therapy. 
In the murine collagen-induces arthritis (CIA) model of inflammatory arthritis, Cl-
amidine showed therapeutic efficacy by decreasing joint and serum citrullination 
content and the relative synovial levels of citrullinated antibodies, resulting in the 
reduction of clinical symptoms severity [97]. In the same mouse model, BB-Cl-
amidine reversed joint clinical and histological inflammation. Indeed, the 
compound inhibited synovial citrullination and significantly reduced immune 
inflammatory infiltrates, mostly due to neutrophils and macrophages. Moreover, 
the drug suppressed pro-inflammatory Th1 and Th17 responses and enhanced Th2-
mediated reactions, demonstrating its immunomodulatory effects[98]. 
In the CIA mouse model, GSK199 efficiency was also tested[99], and PAD4 
selective inhibition significantly ameliorated the disease. Indeed, drug treatment 
reduced cartilage and bone damage and synovial inflammation, which is associated 
Fig. 13. GSK199/PAD4 complex. 
PAD4 residues are shown in cyan, excluding the purple 633-645, which interact with F634 
and V643 of GSK199, represented in yellow. 
After binding of GSK199 to PAD4, a b-hairpin structure is formed and packed on the 
apical side the inhibitor. 







with infiltration of macrophages, lymphocytes, and neutrophils[100]. Peptide 
glucose-6-phosphate isomerase-induced arthritis (pGIA) mouse model following 
Cl-amidine treatment also showed a significant reduction of IL-6 proinflammatory 
cytokine local secretion due to the inhibition of IL-6 gene expression in the joints 
and draining lymph nodes[101]. Consequently, PAD inhibition suppressed the 
severity of arthritis also in this mouse model, as the histopathological score 
demonstrated a significant blockade of inflammatory cell infiltration and release of 
inactive PADs in RA-affected joints, decreasing antibody responses to citrullinated 
epitopes. In addition, the compound prevented NET formation, contributing to less 
production of citrullinated histone antigens and proinflammatory cytokines [102]. 
Apolipoprotein-E (Apoe−/−) knockout atherosclerosis murine model also 
demonstrated a strong therapeutic effect following PAD inhibition. In this disease 
model, where NET formation is enhanced and autoantibodies are released, daily 
injections of Cl-amidine reduced atherosclerotic lesion area and delayed carotid 
artery thrombosis event. These effects were associated with reduced recruitment of 
netting neutrophils and macrophages into aortic sinus lesions[78]. 
In the dextran sulphate sodium mouse model of UC, Cl-amidine reduced clinical 
signs and symptoms after disease onset, mainly due to colon inflammatory lesion 
decreasing[103]. In addition, in the MRL/lpr mouse model of lupus, reduction of 
NET formation and protection of lupus-related vascular and skin damage were 
observed after both Cl- and BB-Cl- amidine. Moreover, the drugs reduced immune 
complex deposition in kidneys and intestinal inflammation[104]. Additionally, 
treated mice significantly reduced proteinuria and renal inflammation, which was 
correlated with less infiltration of leukocytes into the kidney[105]. Also, Cl-amidine 
treatment prevented immune complex deposition and NET release in the glomeruli 
of NZM, an alternative lupus mouse model[58]. In TLR7-mediated disease mouse 
model, treatment with GSK199 decreased neutrophil migration to kidneys and 
impaired ICAM-1-dependent adhesion[106].  
The beneficial therapeutic effects of PAD inhibitors are also reported in 
neurogenerative disorders. Cl-amidine reduced PAD activity dysregulation in 
protein citrullination in the white matter of MOG-induced EAE animal model. 




and the spinal cord of inflammatory cells. Finally, PAD inhibition significantly 
reduced disease progression when administered before disease onset, making 
hypercitrullination a valid therapeutic target in MS[107]. 
Overall, these studies show that, in several inflammatory pathologies, 
pharmacological PAD inhibition leads to therapeutic effects, mostly correlated with 




2. LEUKOCYTE TRAFFICKING 
Leukocytes have the capability to migrate from the blood into the inflamed tissue 
in order to induce an efficient cell response, crucial for the immune surveillance. 
Leukocyte trafficking occurs through tightly regulated leukocyte-endothelial 
interactions (Fig. 14), which are not discrete events but represent synergistic 
contacts among the adhesion molecules, resulting in a complex adhesion 
cascade[108].  
Although additional steps have been included in the classical model of leukocyte 
trafficking, such as slow-rolling, adhesion strengthening and polarization, in this 
thesis we focus on the key adhesive interactions of rolling, arrest, and 
transmigration. 
 
Fig. 14. Key adhesive steps of leukocyte extravasation. 
In the upper panel, all the adhesion molecules that mediate endothelial/leukocyte membrane 
interactions are represented. In the lower panel, the resulting tissue cell recruitment events, 
deeply described in the following paragraphs.  




2. 1. LEUKOCYTE ROLLING 
The interaction of selectin adhesion molecules with their ligands results in 
leukocyte rolling, the first step of leukocyte trafficking. Selectins are the main 
inducers of leukocyte rolling. Inflamed endothelium expresses E-selectin and P-
selectin, whereas leukocytes express L-selectin. The structure of these molecules is 
characterized by an N-terminal lectin domain, an epidermal growth factor-like 
module, a series of tandem consensus repeats, a transmembrane domain, and a 
cytoplasmic tail. The selectins recognize a sialic Lewis X moiety, normally present 
in glycoproteins[109]. P-selectin glycoprotein ligand-1 (PSGL-1), a homodimeric 
mucin on leukocytes, is considered the most important P-selectin ligand, but can 
bind all three selectins.  
The kinetic of selectin-ligand interaction follows a high on- and off- rates of 
binding[108]. Indeed, immune cells form bounds with endothelium at the leading 
edge and dissociate at the trailing edge. Several intrinsic and extrinsic cell factors 
influence leukocyte rolling by modifying the energy of this bound formation. Shear 
stress is defined as the force exerted by blood flow on the endothelial surface and 
supports L-selectin and P-selectin rolling, strengthening each bond whenever shear 
stress is applied[108]. Therefore, cell rolling ends when flow is abolished. Selectin 
ligands are concentrated on the tips of cellular microvilli: their stretching and 
selectin ligand clustering are the main intrinsic factors that increase adhesive 
contacts[110].   
In both selectin and ligand expressing cells, selectin engagement triggers activating 
signals which, together with leukocyte activation through adjacent G-protein-
coupled receptors (GPCRs), lead to leukocyte arrest, the following step of 
leukocyte migration through the endothelium[111]. 
 
2. 2. LEUKOCYTE ARREST 
Leukocyte rolling is followed by cell arrest, which is mediated by endothelium-
integrin adhesive interactions. Leukocyte integrins are transmembrane αβ 




superfamily members, such as ICAM-1 and VCAM-1, in response to a complex 
signaling pathway rapidly triggered by inflammatory chemokines.  
At least 18α and 8β subunits are known to generate 24 integrin heterodimers, 
containing three different domains, such as the extracellular and transmembrane 
domains, and a final cytoplasmic tail, which binds cytoskeletal proteins and 
intracellular signaling molecules [112]. The Very Late Antigen 4 (VLA-4; 
CD49d/CD29; aMb1) and Lymphocyte Function Associated Antigen 1 (LFA-1; 
CD11a/CD18; aLb2) mediate lymphocyte adhesion. In addition to LFA-1, 
neutrophils, which lack blood VLA-4 expression[113, 114], express Macrophage 
Antigen 1 (MAC1; CD11a/CD18;aMb2), which binds ICAM members and 
extracellular matrix components such as fibrinogen[115]. 
Chemokines, such as CXCL12, and generally chemotactic factors, like fMLP, are 
the most important integrin activators[116]. After their binding to specific GPCRs, 
chemokines almost instantaneously trigger a complex intracellular signaling 
network, known as inside-out signaling, which results in rapid integrin activation. 
In order to reach their functional conformation, integrins undergo discrete and 
dramatic structural changes that expose ligand binding sites and increase integrin 
affinity. The term affinity refers to the energy of ligand attractive binding[117]. The 
most detailed information about integrin activation comes from LFA-1 studies. 
LFA-1 extends its conformation from a bent low-affinity conformation to 
intermediate and finally, high-affinity state, which correlates with the opening of 












The intracellular signaling cascade that regulates the integrin affinity is still 
incompletely understood. CXCL12 receptor engagement triggers JAK PTKs and 
heterotrimeric Gai protein, leading to activation of multiple Guanidine Nucleotide 
Exchange Factors (GEFs), which in turn regulate small GTPase activity. Rho and 
Rap are the most studied GTPases involved in LFA-1 signaling. These enzymes 
induce the binding of several actin/integrin proteins, such as talin1, to the 
cytoplasmatic tail of integrin, resulting in LFA-1 activation (Fig. 16)[118].  
Fig. 15. Schematic representation of LFA-1 structural domains and conformational 
changes. 
In the right panel, the distinct α and β subdomains are reported. 
In the left panel, the cytoskeletal rearrangements of LFA-1 structure. The low-affinity bent 
conformation has the a and b cytoplasmic tails in close proximity and the ligand-binding 
site toward the plasma membrane. Inside-out signaling leads to physical interaction with the 
cytoskeletal talin, which separates tails and induces integrin extension. Once bI domain is 
able to bind an internal ligand in the aL I domain (aL-E310), the ICAM-1 ligand-binding 
site is exposed.  
From S. C. Pflugfelder et al, J Ocul Pharmacol Ther, 2017. 
Fig. 16. Model of the inside-out signaling controlling LFA-1 affinity. 
CXCL12 binding to CXCR4 receptor induces the concurrent activation of JAK and Gai 
protein. VAV1 activity is JAK dependent, whereas SOS1, DOCK2 and ARHGEF1 are 
regulated by both the kinase and the Gai protein. The cooperation of these GEFs triggers 
RhoA and Rac1 GTPase activation. RhoA could even stimulate Rap1 activity, which is 
additionally controlled by Gai-dependent PLC.  
Finally, FERMT3, Kindlin3, TLN1, Talin1, CYTH1, Cytohesin-1, RIAM, RASSF5 and 
RAPL bind LFA-1 cytoplasmatic tail, inducing integrin high affinity conformation. 




It is known that the inside-out pathway induces changes in integrin distribution on 
the cell surface leading to integrin clustering, increasing integrin valency, or the 
number of bonds in discrete surface areas. Integrin clustering and allosteric 
conformational changes trigger outside-in signaling, where integrin binding to 
endothelial surface receptors activates signaling pathways inside the cells, resulting 
in adhesion stabilization and cell motility. In this context, Src family kinases are 
established key players in these inner signaling, leading to cell spreading and 
subsequent transmigration of the leukocytes firmly adhered to the endothelium [119]. 
 
2. 3. LEUKOCYTE TRANSMIGRATION 
Paracellular or, less commonly, transcellular are both accepted leukocyte 
transmigration pathways, which mutually occur depending on the stimuli. In the 
paracellular route, integrin ligation to the endothelial adhesion molecules reduces 
the interendothelial tight contacts, resulting in the passage of leukocytes through 
cell junctions. Indeed, entothelial ICAM-1 binding by integrins, leads to Ca2+ level 
increase, which is associated with the activation of MAPK and Rho GTPase, 
inducing cell contraction and cell contact opening. The molecules that might block 
leukocyte entering the endothelium layer, such as E-cadherin, are collocated away 
from the junctional areas. On the contrary, the endothelial junctional molecules, 
such as PECAM-1, which bind their leukocyte counterparts, are distributed at the 
luminal cell surface, resulting in an adhesive gradient that guides cells to the 
junctions[108]. 
In order to migrate transcellularly, through the thin part of the endothelium, 
leukocytes extend cell membrane protrusions into endothelial cells, where integrin- 
ICAM-1 ligation results in the formation of channels through which cells can pass 
through. The molecules involved in the transcellular migration may also mediate 
the endothelial-cell junction route. These molecules include immunoglobulin 
superfamily members PECAM-1, ICAM-1, ICAM-2, JAM-A, JAM-b, JAM-C 
ESAM, and CD99. Therefore, to ensure successful transmigration pathways, 




3. ALZHEIMER'S DISEASE 
AD is the most common cause of dementia. Based on the World Health 
Organization's (WHO) reports, nearly 50 million people have dementia 
worldwide[62]. There are approximately 10 million new cases annually, and 
Alzheimer's disease (AD) may contribute to 60–70% of these cases. AD is usually 
sporadic and commonly occurs in aged people. Both the familial and the sporadic 
forms of AD share a common phenotype converging towards similar 
neuropsychiatric symptoms, emotional disturbance, and the progressive 
impairment of daily activity, resulting in dependency, disability, and mortality[121]. 
The etiology of AD is still unclear, and adequate treatments for this disease are not 
currently available. 
The neuropathological hallmarks of AD include extracellular accumulation of 
plaques containing β-amyloid (Aβ) peptides, intracellular aggregation of 
hyperphosphorylated tau leading to the formation of neurofibrillary tangles (NFTs), 
neuronal death, synaptic loss resulting in brain atrophy, and cerebral chronic sterile 
inflammation[122]. 
Amyloid plaques result from the extracellular accumulation and deposition of Aβ 
peptides, produced by the sequential proteolytic cleavage of the amyloid precursor 
protein (APP) by α-, β-, and γ-secretases, an enzymatic complex composed by 
presenilin 1 (PS1) or presenilin 2 (PS2). An imbalanced production, clearance, and 
aggregation of peptides cause Aβ accumulation. Monomers of Aβ are soluble 
structures that tend to assembly with one another leading to the formation of 
oligomers, which aggregate to form protofibrils in the extracellular matrix or on 
cell surfaces. Protofibrils are the precursors of amyloid fibrils (Fig. 17). Amyloid 
fibrils are highly insoluble and can assemble to form extracellular amyloid plaques, 
which deposit in the brain parenchyma during AD progression. Aβ oligomers are 
the most neurotoxic structures and can alter membrane permeability by forming 
pores and bind to mature synapses on hippocampal and  neurons, leading to the 





NFTs are intraneuronal filamentous inclusions within pyramidal neurons composed 
of hyperphosphorylated and aggregated form of tau protein. Tau is normally a 
soluble axonal protein that promotes assembly and stability of microtubules and 
vesicle transport. Hyperphosphorylated tau becomes insoluble and loses its affinity 
for microtubules, leading to self-association into cytotoxic paired helical filament 
structures (PHF) that accumulate into pyramidal neurons leading to the formation 
of NFTs (Fig. 18). NFTs destabilize microtubules, interfering with axonal flow, and 
leading to the destruction of a vital cell transport system causing neuronal 
degeneration and death[124].  
Fig. 17. Generation of amyloid- β plaques during AD. 
Schematic representation of the two pathways for APP processing and Aβ aggregation. APP 
(605-770 aa) can be processed through the amyloidogenic pathway, which depends on β-, and 
γ-secretases, or through the non-amyloidogenic pathway, that involves α- and γ-secretases. 
The first pathway leads to the Aβ peptide formation, whereas the other demolishes the 
production of Aβ protein. In physiological condition the major part of APP (90%) is processed 
by non-amyloidogenic pathway, while the remaining part (10%) follows the other pathway. 
From F. L. Heppner, Nat Rev Neurosci, 2015. 
Fig. 18. Neurofibrillary tangle formation in AD. 
Key events in the NFT formation are shown. Tau stabilizes axonal microtubule structures 
during physiological conditions. Tau mutations and dysregulation of kinases/phosphatases 
lead to hyperphosphorylated form of the protein, which results in microtubule 
depolymerization, tau dysfunction and axonal defects.   





The progressive development of AD is associated with an intense neuronal loss, 
which determines brain atrophy. This loss of neurons is highly selective for specific 
brain areas, such as hippocampal field CA1, subiculum, and entorhinal cortex. 
Furthermore, during the pathological process, neuronal loss is also extended to the 
temporal, frontal, and parietal cortex. Synaptic loss occurs in the same regions 
where neuronal loss takes place[125]. 
 
3. 1. NEUROINFLAMMATION IN AD 
Chronic neuroinflammation has a central role in the pathogenesis of AD. 
Neuroinflammation is mainly driven by microglia, the resident phagocyte of the 
CNS, and astrocytes. Microglial cells provide immune brain surveillance, 
microenvironment scanning, and maintenance of neuronal plasticity through the 
release of trophic factors[126]. However, in AD, their continuous activation leads to 
detrimental effects. Indeed, microglia can be activated by Aβ oligomers and tau 
proteins, recognized as PAMPs, via cell-surface receptors. In response to receptor 
ligation, microglia clears Aβ by phagocytosis or by the release of enzymes that are 
able to degrade Aβ in the extracellular space. However, in AD, the clearance 
mechanism of Aβ can be compromised, leading to excessive accumulation of Aβ 
and neuronal debris[126]. In addition, activated microglia induces an increase in tau 
phosphorylation levels. In fact, during neuroinflammation, microglial cells secrete 
IL-6 to activate kinases, such as cyclin-dependent kinase 5 (Cdk5), p38-MAPK, 
and GSK3β producing abnormal tau hyperphosphorylation[127].  
Peripheral inflammatory cells also play a crucial role in the onset and progression 
of the disease, infiltrating the CNS through a dysfunctional BBB[128]. Circulating 
leukocyte subpopulations were identified in the brains of patients with AD and in 
animal models of AD. Although their role in the disease progression remains 
unclear, both CD4+ and CD8+ T cells were found to adhere to the vascular 
endothelium and migrate into the parenchyma. Our unpublished data also reveal 
that lymphocytes infiltrate the brain during AD progression: at early disease stages, 
the frequency of CD8+ T cells was higher compared to CD4+ cells in 3xTg-AD 




conversely, CD4+ T cells gradually increased with time, showing a peak of 
accumulation at 9 months of age. In addition to lymphocytes, neutrophils, which 
are the most abundant leukocytes in the human circulation, adhere to cerebral 
vessels and migrate into the AD brain. They migrate into the parenchyma of mouse 
models of AD at the onset of memory deficit, secreting IL-17 and producing NETs, 
which may harm endothelial and neural cells, contributing to AD pathogenesis and 
cognitive impairment. Integrin LFA-1 is the primary adhesion molecule responsible 
for the intravascular adhesion and intraparenchymal migration of neutrophils in the 
brains of 3xTg-AD mice[65].  
Recently, we demonstrated that circulating CD4+ T cells as well as a significant 
proportion of blood CD8+ T cells expressed higher levels of VLA-4 integrin 
compared to wild type animals, suggesting a role for this integrin in the peripheral 
leukocyte recruitment in the AD brain. Indeed, our recent studies demonstrated that 
blockade of alpha4 integrins leads to improved memory and reduced 
neuropathology in 3xTg-AD mice [113]. Interestingly, plasma samples from AD 
patients show higher levels of soluble VCAM-1, the endothelial counterligand of 
VLA-4, expression than controls, suggesting a role for VLA-4 and VCAM-1 
adhesion molecules in lymphocyte migration during AD[113]. In addition, 
unpublished data from our laboratory demonstrated the presence of an activated  
circulating T cell population, which highly expresses LFA-1 integrin and showed 
that LFA-1 depletion led to an amelioration of cognitive functions and 
neuropathological hallmarks of the disease in 3xTg-AD animals. Therefore, VLA-
4 and LFA-1 integrins may represent key molecular pathways for leukocyte 
adhesion on brain endothelial cells and migration into the CNS during AD. 
  
3. 2. THE 3xTg-AD MOUSE MODEL OF AD 
The triple transgenic mouse (3xTg-AD) generated by the group of Dr. La Ferla is 
among the most commonly used AD models reproducing the main features of 
human AD pathology[129]. Indeed,  3xTg-AD model develops an age-related 




pathology due to the expression of three human mutant genes, observed in AD 
familial patients: PS1 (M146V), βAPP (Swedish), and tau (P301L)[130].  
From a pathological point of view, in 3xTg-AD mice, the Aβ deposits initially 
accumulate intracellularly at 6 months of age and become marked at 12 months in 
cortical regions and hippocampus. By 15 months, Aβ plaques appear in posterior 
cortical regions such as the occipital and parietal cortices. Although tau 
hyperphosphorylation is present during early disease stages, NFTs are evident at 
12-18 months of age in the hippocampus, then they progress to the cortex, 
suggesting that their formation may be influenced by the generation of Aβ[131]. At 
6 months of age, 3xTg-AD mice show neuropathological changes and cognitive 





MATHERIALS and METHODS 
1. REAGENTS  
The following fluorescence-labelled antibodies were purchased from the indicated 
commercial sources: anti-mouse CD45 (BD HorizonTM clone 30-F11), Ly6G 
(Biologend clone 1A8), B220 (BD PharmigenTM clone RA3-6B2), CD4 (BD 
PharmigenTM cloneRM4-5), CD8 (Biolegend clone 53-6-7), CD3 (BD HorizonTM 
clone 17A2), GD (BD HorizonTM clone GL3). We also used 7-AAD Viability 
Staining Solution from Biolegend. 
Anti-mouse ionized calcium-binding adaptor molecule-1 antibody (Iba-1) was 
purchased from Wako, anti-human Aβ (clone 6E10) from Covance, anti-human 
total tau (clone HT7), and phospho-tau Thr231 (clone AT180) from Thermo Fisher. 
Biotinylated secondary antibodies were purchased from Sigma-Aldrich. 
SMARTpool ON-TARGET siRNAs were purchased from Dharmacon, whereas 
human T Cell NucleofectorTM Kit (Cat. No VPA-1002) from Lonza Bioscience. We 
also anti-human PAD2 (ab183194) from Abcam.  
BB-Cl-amidine and GSK199 were gently provided by P. Thompson, Professor and 
Director of Chemical Biology at the University of Massachusetts Medical School-
Worcester MA. 
Human CXCL12, murine ICAM-1 and VCAM-1, and TNF-a were obtained from 
R&D Systems, human plasma fibrinogen (AF 3879-1G) from Sigma-Aldrich. 
We bought the oligomeric Ab1-42 from GenScript. Monoclonal anti-human KIM127 
and IB4 (b2 integrin) were purchased from ATCC. We also used anti-human VLA-
4 (BD PharmigenTM  555503) and CXCR4 (Biolgend 1245). Anti-mouse IgG-FITC 
were obtained from Sigma-Aldrich (F2012). 
 
2. PRIMARY HUMAN CELLS 
Human studies were approved by the University of Verona Ethics Committee. 
Neutrophils and lymphocytes were isolated from peripheral blood of healthy donors 




After erythrocyte sedimentation (4:1 ratio of blood to 4% dextran), the neutrophil 
cell suspension was washed in Phosphate-Buffered Saline (PBS) 1X and 
erythrocyte lysis was performed (0.2% hypotonic NaCl solution followed by 1.2 % 
isotonic NaCl solution). After gradient sedimentation, mononuclear cell fraction 
was loaded onto a discontinuous Percoll gradient in order to collect human 
lymphocytes.  
 
3. PRIMARY MURINE CELLS 
Neutrophils were isolated from the bone marrow of 3 months of age C57BL/6J 
mice. Tibias and femurs were surgically removed, and bone marrow cells were 
rapidly flushed out of the bones with Hank's Balanced Salt Solution (HBSS) 1X 
supplemented with 0.1% Bovine Serum Albumin (BSA). After erythrocyte lysis (as 
explained in paragraph n2), cells were stratified onto discontinues Percoll gradient. 
After 30min of centrifugation, the neutrophil ring was collected. 
Lymphocytes were isolated from draining lymph nodes of 3 months of age 
C57BL/6J mice. Lymph nodes were removed, transferred onto a 70-μm cell strainer 
fitted on a 50mL tube, and gently smashed by using a syringe plunger. The resulting 
cell suspension was finally washed in PBS 1X. 
 
4. CELL TREATMENT 
5 × 106 of neutrophils and lymphocytes, isolated as described above, were 
resuspended in 1mL of standard adhesion buffer (PBS 1X + 10% FBS + Ca2+ 1 mM 
+ Mg2+ 1 mM, pH 7.2). Then, cells were incubated with BB-Cl-amidine or GSK199 
(1 µM -5 µM -10 µM - 20 µM) for 30min at 37°C. Control and vehicle samples 






5. VIABILITY ASSAY 
Vybrant™ DyeCycle™ Violet/SYTOX™ AADvanced™ Apoptosis Kit 
(Invitrogen) was used to identify viable cell fraction. 500.000 cells were 
resuspended in 100µL of antibody mix (998µL of HBSS 1X, 1µL of Vybrant™, 
and 1µL of SYTOX™) and incubated for 15min protecting from light. 
Fluorescence emission at 440 nm and 660 nm was finally measured by 
MACSQuant Analyzer (Miltenyi Biotec). 
 
6. STATIC ADHESION ASSAY 
Neutrophils or lymphocytes were resuspended in standard adhesion buffer at a final 
concentration of 5 × 106/mL.  Adhesion assays were performed on 12-well glass 
slides coated with 20 µL of ICAM-1 or VCAM-1 (µg/mL), or with 20 µL of 
fibrinogen (1mg/mL). 20 μl of cell suspension were added to the wells and 
stimulated with 5 μl of chemokine, as suggested by A. Montresor et al., 2018[116]. 
Lymphocytes were stimulated 3min with CXCL12 (200 nM or 500nM for human 
or murine cells, respectively). PMN were stimulated for 60 sec with fMLP (1nM 
for human cells; 1µM for murine cells) or oligomeric Ab1-42 ( 5µM or 7µM for 
human or murine neutrophils). Moreover, human neutrophils were stimulated with 
10ng/mL TNF-a for 15min. After rapid washing in ice-cold PBS 1X, adherent cells 
were fixed in glutaraldehyde 1.5% (V/V) and counted by ImageJ-assisted 
enumeration. 
 
7. siRNA TECHNIQUES  
PAD2 targeting mRNA silencing was performed by AMAXA nucleofector, 
following the manufacturer's instructions. 5 × 106 per sample of human 
lymphocytes were resuspended in 100µL of Nucleofector Solution combined with 
20nM of SmartPool ON-TARGET plus siRNAs. The cell suspension was first 




U-15 Nucleofector Program was chosen. The efficacy of gene silencing was 
assessed after 12 hours by immunoblotting. 
 
8. IMMUNOBLOTTING 
Cells were lysed in ice-cold RIPA lysis buffer supplemented with a complete 
protease inhibitor cocktail (Roche). Bradford protein assay (Bio-Rad) was 
performed in order to quantify protein content. An equal amount of proteins was 
separated through 10% SDS-PAGE electrophoresis. After protein transfer from the 
gel to a nitrocellulose membrane, the unspecific binding was blocked with 3% 
bovine serum albumin (BSA), and after 1 hour of incubation, the filter was stained 
by anti-human PAD2 Ab (1:200) overnight. HRP-coupled secondary antibody (GE 
Healthcare Life Science) was added after rapid membrane washing with PBS 1X + 
0,2% Tween 20. Finally, immunoreactive bands were visualized by the ECL 
detection kit (Merck Millipore), acquired by ImageQuant Las4000 (GE Healthcare 
Life Science), and quantified by densitometric analysis (Quantity One, Bio-Rad). 
 
9. MEASUREMENT OF LFA-1 AFFINITY STATES 
Human lymphocytes were resuspended in standard adhesion buffer at the 
concentration of 2 x 106/mL and briefly (3min) treated with 10 μg/mL of KIM127 
antibody, as reported by A. Montresor at al., 2018[116]. 10min of 50nM CXCL12 
incubation followed at 37°C. After rapid washing, cells were stained by anti-mouse 
FITC secondary polyclonal antibody and analyzed by MACSQuant Analyzer 
(Miltenyi Biotec). 
 
10. CXCR4, VLA-4, AND LFA-1 PROTEIN EXPRESSION 
Human primary lymphocytes were treated with PAD inhibitors (see paragraph n.4). 




following PE-conjugated antibodies: anti-human CXCR4 (1:200) and VLA-4 
(1:200) for 20min at RT, protecting cells from light.  
500.000 cells were also labelled with anti-human IB4 (1:200). After 20 min of 
staining with the primary antibody, lymphocytes were washed and incubated with 
anti-mouse FITC-conjugated secondary antibody (1:200) for 20min. Finally, 
samples were analyzed by MACSQuant Analyzer (Miltenyi Biotec).  
 
11. MICE 
3xTg-AD mice (MMRRC stock no. 34830-JAX) and wild-type control 
B6129SF2/J (stock no. 101045) were purchased from the Jackson Laboratory. 
3xTg-AD mouse expresses the human mutant APP and PS1M146V, associated 
with familial AD, and the TauP301L allele. Therefore, it develops both amyloid 
and tau pathologies.  
Animals were housed in pathogen-free and climate-controlled conditions, provided 
with food and water ad libitum. The experiments were conducted following the 
principles of the NIH Guide for the Use and Care of Laboratory Animals and the 
European Community Council.  
 
12. TREATMENT OF MICE 
6 months of age 3xTg-AD and B6129SF2/J were given a daily i.p. injection with 5 
mg/Kg of BB-Cl-amidine or 30 mg/Kg of GSK199, while B6129SF2/J and 3xTg-
AD control mice were treated with vehicle (DMSO). We studied the effects of drugs 
both in males and females, approximately 15 animals per group.  Treatment was 
continued for 4 weeks, and then mice were left untouched for one month, allowing 







13. BEHAVIOURAL ASSESSMENTS  
Before proceeding with behavioral tests, mice were selected on the basis of precise 
criteria. We excluded mice with body weight higher than 40g or with evident 
physical and cutaneous defects. Hindlimb clasping and Ledge test were performed 
as pre-cognitive tests in order to identify general deficits which could affect task 
performance, such as alterations in vestibular function.  
Behavioral tests were performed during the light phase of the circadian cycle. We 
started from the Y-maze to conclude with the most stressful Contextual Fear 
Conditioning (CFC), reducing all possible stress-related variables. We conducted 
cognitive tests, as we previously illustrated by our group[65]. Experiments and 
analyses were conducted in a random and blinded fashion with respect to genotype 
and treatment.  
At the end of behavioral tests, 5 mice per group were intracardially perfused by 
cold 4% paraformaldehyde (PFA) in order to collect brains and perform 
neuropathological analysis. 5 animals per group were intracardially perfused by 
cold PBS 1X, and brains were next digested for the isolation of infiltrating 
leukocytes. The remaining animal organs were fixed in 4% PFA or perfused in PBS 
1X and stocked for future studies of immunohistochemical and proteomic analysis, 
respectively. 
 
14. PRE-COGNITIVE TESTS  
Ledge test was performed to directly measure animal coordination[132]. The mouse 
was observed walking along the cage ledge and lowering itself into its cage. A score 
of 0 corresponded to a mouse that walked without losing its equilibrium and 
lowered itself into the cage using its pawns. If the mouse lost its balance but 
coordinately moved, the score assigned was 1. It received 2 points when it did not 
use its pawns to descend into the cage. If the animal refused to move or fell off the 
ledge while walking, the assessed score was 3.  
Hindlimb clasping tested neurodegeneration progression[132]. The mouse was 




these were away from the abdomen, it was assigned a score of 0. It received 1 when 
one hindlimb was retracted toward the abdomen. If both hindlimbs were partially 
retracted, the score was 2, while it was 3 in case of hindlimbs totally retracted for 
more than 5sec. 
Both the tests were performed four times, calculating finally an average score. 
 
15. SPONTANEOUS ALTERNATION Y-MAZE TEST  
Y Maze Spontaneous Alternation is a behavioral test that allows researchers to 
assess hippocampus-dependent spatial working memory in rodents. Each mouse 
was placed in the center of a symmetrical Y-maze equipped with three arms (A, B, 
and C), collocated at 120° angle from each other.  The animal had 8min to freely 
explore the environment and enter the arms of the maze. The sequence and the total 
number of arm entrances were recorded. The entrance into one arm was assessed 
when murine pawns were entirely inside it. The alternation percentage was 
calculated based on the entries into the three arms in overlapping triple sets (e.g., 
ABC but not ABA). To reduce odor cue influences, the maze was cleaned with 70% 
ethanol.  
 
16. CONTEXTUAL FEAR CONDITIONING TEST 
CFC was performed in order to evaluate rodent fear learning and memory. Mice 
were trained and tested on two consecutive days. During training, each animal was 
placed in a 30 × 24 × 21 chamber (Ugo Basile) for 2min, providing a white 
illuminating and a 2 Hz tone stimulus. The sound terminated with a 2sec foot shock 
(1.5 mA). These stimuli were repeated twice at 2min intervals. After 20 hours of 
resting, mice returned to the chamber for the contextual testing, with the same white 
cage illumination but without tone or shock.  During the 5min session, ANY-maze 
software recorded mouse freezing behavior, which means a lack of movement. 
After 2 hours of resting, the fear memory test was performed. The chamber was 




novel odor in order to create an unexplored environment, where mice were exposed 
only to the auditory cue. The freezing response was then scored. Fear learning and 
memory was finally calculated by subtracting the percentage of freezing obtained 
in the last test session from that recorded in the contextual environment.  
 
17. INTRACARDIAL PERFUSION 
Mice were exposed to isoflurane inhalation, and once anesthetized, they were 
placed on a surgical support, flatting on their backs. After stretching and pinning 
the paws, skin and ribs were cut to make the heart accessible. The right atrium was 
incised, while a butterfly needle connected to a peristaltic pump (Minipuls3 
GILSON®) was inserted in the left ventricle. The pump injected 25mL of PBS 1X 
supplemented with 1mM Ca2+/Mg2+ (buffer solution) into the systemic circulation. 
Once all the blood was washed away, the buffer solution was replaced with 25mL 
of cold 4% PFA in order to fix the organs.  
 
18. HISTOPATHOLOGICAL ANALYSIS 
PFA perfused brains were collected, overnight fixed in 4% PFA, and stocked in 
cryoprotectant solution (PBS 1X containing 30% sucrose and 7 mM sodium azide). 
The organs were mounted through optimum cutting temperature (OCT) embedding 
compound (DDK Italia) and cut into 30μm coronal sections.  
Tissue sections were treated with a specific antigen retrieval solution using 70% 
formic acid for Ab staining and with a pre-heated 10 mM sodium citrate buffer (pH 
8.5) for tau or microglia staining. Free floating brain slices were incubated in 
blocking solution with (2% normal goat serum and 0.4% Triton X-100) for 1 hour 
at RT and then treated overnight with the following primary antibodies: anti-mouse 
Iba-1(1:500), anti-human Aβ (1:1000) or anti-human total and phospho-tau 
antibody (1:200). After washing with PBS 1X + 0.05% Tween-20 for 10 minutes, 
3% H2O2 was added to the wells at RT to block endogenous peroxidase. Thereafter, 




anti-mouse secondary antibodies (1:200). Immunoreactivity was visualized using 
the VECTASTAIN ABC kit (Vector) and Vector NovaRED (Vector) as 
chromogen. Finally, the sections were washed with distilled water, transferred to 
glass slides, dehydrated, and mounted with Eukitt mounting medium (Sigma-
Aldrich).  
 
19. MICROGLIA, Aβ AND TAU QUANTIFICATION 
Images were blindly acquired with the Axio Imager Z2 microscope (Zeiss). The 
areas covered by Iba-1+ microglial cells, Aβ deposits, total tau, and phospho-tau 
positive neurons were blindly quantified using ImageJ v1.32j software. Sections 
were acquired from the anterior hippocampus through the bregma – 2.9 mm at an 
intersection interval of 500 μm (every fourth section) – in order to analyze the whole 
area of the cortex and the hippocampus.  
 
20. ISOLATION OF BRAIN INFILTRATING LEUKOCYTES 
Mouse perfused brains were collected and homogenized by Gentle MACSTM Octo 
Dissociator (Miltenyi Biotec). Tissue was digested with 40 U/mL of DNaseI 
(Thermo Fisher) and 1 mg/mL collagenase (Sigma) at 37°C for 45min. After 
washing and centrifugation, the pellet was resuspended in 30% Percoll. Cell 
suspension was filtered through a 70-μm cell strainer and loaded onto 70% Percoll. 
Leukocytes were isolated at the interface of the discontinuous density gradient, 
washed and labelled with the following anti-mouse antibodies (1µL in 100µL of 
PBS 1X+10% FBS): CD45 BV510, Ly6G FITC, B220 APC, CD4 PE-Cy7, CD8 







21. FLOW CYTOMETRY INSTRUMENTATION 
Cytofluorimetric analysis of the methods described in the paragraphs n 5, 9 and 10, 
were performed using MACSQuant Analyzer (Miltenyi Biotec). Brain infiltrating 
leukocytes, isolated as illustrated in the previous section, were acquired by BD LSR 
Fortessa (BD Biosciences). These samples were analyzed using a spillover-
compensated matrix. Leukocytes were individually stained (single-stained) for each 
marker used and cytometer laser voltages were adjusted to obtain a good separation 
between the negative and positive peaks (highest stain index) for each 
fluorochrome. The compensation matrix was then calculated by adjusting the 
median fluorescence intensity of each fluorochrome in the remaining channels to 
that of the negative peak. The optic baseline of the instrument was calculated and 
applied before each experiment using the cytometer setup and tracking (CST) beads 
to achieve optimal reproducibility between experiments. Post hoc analysis of the 
data, including cell percentages, geometric mean (GEO MEAN) and mean 
fluorescence intensity (MFI) were obtained using FlowJo software. 
 
22. STATISTICAL ANALYSIS 
All data were represented using Prism 6 (GraphPad Software), which was also used 
for statistical analysis. A two-tailed Student's t-test was used for the statistical 
comparison of two samples. One-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test was used to determine differences in means 
among multiple comparisons. Quantitative data are shown as mean values ± 
standard error (SEM).  




AIM OF THE STUDY 
Citrullination is a post-translation protein modification in which PADs convert the 
arginine into a citrulline residue in a calcium-dependent manner. The result is a 
shift of the protein charge, from positive to neutral, that could modulate several 
physiological and pathological processes by affecting protein-protein interactions, 
hydrogen bond formation, protein structure or protein denaturation. Immune cells 
selectively express the isoforms 2 and 4, which are physiologically involved in 
inflammatory responses through NET formation. Hyperactivation of these two 
PAD members correlates with a dysregulation in ET release and clearance, leading 
to cell toxicity and immunogenic reactions.  
PAD-catalyzed citrullination is involved in several inflammatory and autoimmune 
disorders such as RA, UC, SLE, MS and AD.  Pharmacological PAD inhibition has 
brought beneficial therapeutic effects for these pathologies, resulting in an 
amelioration of the general inflammation and reducing the immune cell recruitment 
to the inflamed tissue. As a direct involvement of PAD2 and 4 in immune cell 
trafficking has not yet been investigated, the aim of this project was to study the 
role of PADs in neutrophil and lymphocyte adhesion under physiological and 
pathological conditions and determine the effect of PAD inhibition on brain 






1. CELL TREATMENT WITH BB-CL-AMIDINE OR GSK199 IS 
NOT CYTOTOXIC 
Previous studies have demonstrated that PAD2 and PAD4 inhibitors significantly 
reduced leukocyte infiltration in inflammatory diseases[57, 78, 98, 106]. However, how 
these isoforms directly affect immune cell trafficking in the context of 
inflammation has not yet been investigated. To address the hypothesis that 
leukocyte treatment with PAD inhibitors could impair leukocyte adhesiveness, we 
firstly tested the cytotoxic effect of the drugs. Human neutrophils and lymphocytes 
were treated with increasing concentrations of BB-Cl-amidine, a pan PAD 
inhibitor, and GSK199, which selectively blocks PAD4 catalytic activity. 
Vybrant/Sytox staining, followed by FACS analysis, was performed in order to 
quantified cell viable fraction. As it is reported in Fig. 19, PAD blocking did not 
induce apoptotic or necrotic effects since no statistical differences were found 
between treated and untreated leukocytes in terms of cell viability. We performed 
the same viability assays on treated primary murine leukocytes, resulting in 






2. PADs MEDIATE NEUTROPHIL b2 INTEGRIN-DEPENDENT 
ADHESION 
Proinflammatory chemokines and other chemoattractants activate b2 and b1 
integrins to an extended conformation with high binding affinity for their 
endothelial ligands. Neutrophils express b2 integrins, which binds ICAM members 
and fibrinogen extracellular matrix component. In order to study the role of 
Fig. 19. PAD inhibitor treated leukocytes maintain the same cell survival levels of 
untreated cells. (a-b) FACS analysis showing the viability percentage of human a) 
neutrophils and b) lymphocytes after PAD blocking. Treated cells were incubated with 
indicated µM inhibitor concentrations, whereas DMSO (vehicle) was added to controls 
(ctrl) at the same µM dose present in 20µM condition. After 15min of Vybrant/Sytox dye 
staining, fluorescence emission at 440 nm and 660nm was measured. Data represent mean 






citrullination in immune cell recruitment, we investigated the effects of PAD 
inhibitors on b2 integrin-dependent neutrophil adhesion. 
Static adhesion assay results, illustrated in Fig. 20, showed that PAD inhibition 
significantly impaired the capability of neutrophils to bind the integrin-ligand 
fibrinogen upon fMLP chemokine stimulus. Interestingly, BB-Cl-amidine, which 
inhibits both PAD2 and PAD4, induced a stronger blockade of neutrophil adhesion 
compared to PAD4 specific inhibition induced by GSK199, suggesting a potential 
additive effect between PAD2 and PAD4 isoforms. The comparison between 
human and murine data revealed that the drugs worked efficiently on both in human 
and mouse cells, suggesting PADs in leukocyte adhesion may be conserved in 
mammals.     
Fig. 20. fMLP-induced neutrophil adhesion is impaired after BB-Cl-amidine or 
GSK199 cell treatment.  
(a-b) Static adhesion assays showing the percentage of a) human and b) murine adherent 
neutrophils after PAD blocking treatment. Cells were spotted in 12-well glass slides coated 
with human plasma fibrinogen and were stimulated for 1min with 1nM (human) or 1 µM 
(murine) fMLP chemokine. Adherent cell number is reported as mean values of 4 
independent experiments; error bars represent SEM. (* P < 0.05; Mann-Whitney test)  
a)  




To further investigate the role of PADs in adhesion, neutrophils pre-treated with 
PAD inhibitors were exposed to proinflammatory TNF-a cytokine in order to 
induce a neutrophil integrin transition from basal to primed state, which was 
reported to enhance adhesion molecule expression and to facilitate the migration of 
circulating neutrophils[133] (Fig. 21). The results confirmed our findings from Fig. 
20 demonstrating a role for PAD2 and PAD4 in integrin-dependent neutrophil 
adhesion. Indeed, upon proinflammatory cytokine activation, both BB-Cl-amidine 
and GSK199 inhibited integrin binding to fibrinogen and decreased the percentage 
of adherent cells compared to untreated control cells.  
 
3. PADs MEDIATE LYMPHOCYTE INTEGRIN-DEPENDENT 
ADHESION  
We next investigated whether PADs control adhesion also in human and murine T-
lymphocytes. Lymphocyte firm adhesion in vivo is mainly mediated by VLA-4 and 
LFA-1 integrins, which belong to b1 and  b2 subtypes, respectively. CXCL12 is 
among the most important inducer of integrin ligand binding in lymphocytes. VLA-
4 interacts with the endothelial counterpart VCAM-1, whereas LFA-1 shows high 
binding affinity for the ICAM-1 receptor. We performed static adhesion assays to 
Fig. 21. BB-Cl-amidine or GSK199 inhibit human neutrophil adhesiveness after TNF-
a priming.  
Static adhesion assays representing the inhibitory effects of PAD blocking on the 
percentage of adherent human neutrophils. Cells were pre-incubated with the indicated µM 
drug concentrations for 15min and stimulated with 10ng/mL of human TNF- a. 
Spontaneous cell adhesion was recorded after 3 min. Adherent cell number is reported as 





evaluate the effect of BB-Cl-amidine and GSK199 inhibitors on CXCL12-triggered 
rapid cell adhesion. Pan PAD blockade led to a strong dose-dependent decrease in 
b1 and b2 integrin-dependent adhesion of human T cells on VCAM-1 and ICAM-
1 endothelial ligands, respectively (Fig. 22a). PAD4 specific inhibitor GSK199 also 
impaired b2 integrin-dependent binding to ICAM-1, although its effect was slightly 
less prominent comparing to BB-Cl-amidine. Regarding the adhesion on VCAM-1 
adhesion molecule, we observed a dose-dependent decrease trend using GSK199 
and the effect was clearly less pronounced comparing with BB-Cl-amidine (Fig. 
22b). Our human data were confirmed by results showing that PAD inhibition also 
blocks murine T cell adhesion, with BB-Cl-amidine having a stronger effect that 
GSK199 (Fig. 22c). Together, our data show that PAD2 and PAD4 have a role in 
integrin-dependent adhesion in neutrophils and lymphocytes and that PAD2 is the 









ICAM-1 coating  VCAM-1 coating  
ICAM-1 coating  VCAM-1 coating  
Fig. 22. Lymphocyte PAD blockade impairs integrin-dependent binding to endothelial 
adhesion molecules. 
(a-c) Static adhesion assays representing PAD regulation of lymphocyte firm adhesion. a, 
b) Human primary cells were treated with indicated µM concentrations of BB-Cl-amidine 
and GSK199, or not (ctrl). After 30min of incubation, lymphocytes were spotted on 12-well 
glass slides coated with human ICAM-1 or VCAM-1 and were stimulated with 200nM 
CXCL12 for 3min. c) Static adhesion assays representing the inhibitory effects of PAD 
blocking on the percentage of murine T lymphocytes adhering on ICAM-1. Cells were 
stimulated with 500nM CXCL12 for 3min. Adherent cell number is reported as mean values 





4. PAD2 INHIBITION USING siRNAs LEADS TO RAPID 
ADHESION BLOCKADE IN VITRO  
BB-CL-amidine and GSK199 are described as specific inhibitors of PAD 
catalytic activity. However, because they may potentially have non-specific 
effects, we next seek to confirmed the data obtained above by performing 
experiments using mRNA silencing of PADs. Considering that we could not 
study the effect of the single PAD2 isoform, since only pan PAD and PAD4 
inhibitors were available, we transfected human lymphocytes with a pool of 
four different siRNAs specific for PAD2 mRNA.  
a) b) 
Fig. 23. PAD2 siRNAs mediate efficient and safe protein downregulation in human 
lymphocytes. 
(a-c) Cells were electroporated with a pool of four off-target scrambles or PAD2 specific 
siRNAs and kept in culture for 12h. a) PAD2 and actin immunoreactive bands are shown. 
b) Densitometric quantification of band intensity normalized to the actin (a). Mean values 
from 3 independent experiment are represented; Error bars express SEM (*P<0.05; Mann 
Whitney test). c) FACS analysis showing the viability percentage of human lymphocytes 
after electroporation (following by scrambled or PAD2 siRNA introduction) or not (ctrl). 
Cell viability was measured by Vybrant/Sytox viable dyes. Data represent mean ± SEM 






The efficacy of gene expression silencing was assessed at 12 h after transfection by 
immunoblotting (Fig. 23a-b). Before evaluating the functional effect of mRNA 
silencing in static adhesion assays, we monitored cell survival following 
electroporation to exclude a significant effect on cell viability due to the application 
of an electric field. As shown in Fig. 23c, the electroporation was safe, as it 
maintained the survival at comparable levels of non-electroporated cells used as 
control. Moreover, we compared the viability results obtained from a pool of non-
targeting scrambled siRNAs with those from PAD2-targeting siRNAs. These 
samples retained a similar percentage of live cells, demonstrating that PAD2 







Fig. 24. CXCL12-dependent rapid lymphocyte adhesion is reduced after PAD2 
targeting using siRNA and electroporation. 
Static adhesion assays were performed on 12-well glass slides coated with human ICAM-
1(left panel) and VCAM-1 (left panel). After 12h cell transfection, lymphocytes designed to 
drug treatment were incubated with 20µM GSK199. After half an hour, all the indicated 
samples were stimulated with 200nM CXCL-12 for 3min. Adherent cell number is reported 
as mean values of 3 independent experiments; error bars represent SEM.   








Next, we performed adhesion assays and our data demonstrated that human 
lymphocytes showing reduced expression of PAD2 protein, displayed an impaired 
CXCL12-triggered rapid adhesion to both ICAM-1 and VCAM-1 integrin ligands 
in vitro (Fig. 24).  
Moreover, we pre-treated siRNA transfected cells with GSK199 in order to evaluate 
a potential additive effect between PAD2 and PAD4, previously suggested by the 
stronger inhibitory effect of BB-Cl-amidine. The results confirmed that the two 
isoforms cooperated in the induction of LFA-1-dependent lymphocytes adhesion to 
ICAM-1 since PAD2 silencing performed less efficiently than GSK199 pre-treated 
transfected cells. Moreover, PAD2 silencing supported the pharmacological results 
that PAD4 catalytic activity is not required in VLA-4/b1-dependent adhesion since 
GSK199 had no significant effect on adhesion in PAD2 silenced cells.   
 
5. PADs MEDIATE INSIDE-OUT ADHESION PATHWAY  
The data shown above demonstrate that PADs control leukocyte b1 and b2 integrin-
dependent adhesion, suggesting that these enzymes are involved in an activating 
intracellular signaling pathway common between these two integrins. To further 
characterize PADs role in adhesion triggering, we studied the effect of PAD 
blockade on integrin conformational changes triggered by CXCL12, focusing on 
LFA-1 integrin.  
LFA-1 is the best-characterized integrin undergoing structural conformational 
changes consistent with a progressive affinity increase. Notably, we found that BB-
Cl-amidine treatment completely prevented LFA-1 transition to an extended 
conformation in human lymphocytes, specifically evidenced by KIM127 Ab 
binding, detecting LFA-1 activation epitope corresponding to the intermediate 




GSK199 also inhibited integrin conformational changes, although, as expected, less 
efficiently, in line with the results previously shown in Fig. 4 and 6, and suggesting 
a less prominent role for PAD4 in integrin affinity induction. Therefore, KIM127 
mAb staining revealed that PADs participate in the signaling cascade controlling 
integrin activation and indicated that PAD2 and PAD4 cooperate to induce rapid 
integrin affinity increase leading to leukocyte adhesion. 
 
6. PAD INHIBITION DOES NOT ALTER INTEGRIN EXPRESSION  
The intracellular inside-out signaling starts from chemokine receptor engagement, 
which in turn triggers downstream GPCR-mediated signaling that proceeds in a 
cascade-like fashion, finally inducing integrin binding to endothelial adhesion 
molecules. To exclude the possibility that the effect of PAD blocking on integrin 
activation and leukocyte adhesion may be due to other cellular processes, such as 
decrease in  surface integrin expression, we next performed flow cytometry 
experiments. 
Fig. 25. PADs control the CXCL-12 induced LFA-1 intermediate affinity state. 
MAb KIM127 detection of LFA-1 affinity upregulation after PAD blocking is reported. 
Human lymphocytes were treated with indicated drug concentrations or not (ctrl) for 
30min. After half an hour, cells were incubated with 10 μg/mL of KIM127 for 3min and 
then stimulated for 10min with 50nM of CXCL12 at 37°C. Induction of intermediate state 
was finally quantified by FACS analysis. The result is reported as fold increase between 
resting (without adding chemokine) and CXCL12 stimulated cells. The values were finally 
normalizing on the expression level of untreated cells. Data represent mean ± SEM of 3 






Our data showed that PAD inhibitors have no effect on integrin expression, 
confirming a direct role of PADs in the control of inside out pathways leading to 
integrin activation. Indeed, our data show comparable protein expression levels of 
chemokine receptor CXCR4, b2 and b1 integrins between treated and untreated 
cells, suggesting that adhesion and integrin conformational changes were not 
reduced by unspecific drug effects, but the inhibitory effects observed were due to 
interference with intracellular signalling pathways (Fig. 26).  
 
7. PADs CONTROL Ab1-42-DEPENDENT INTEGRIN ADHESION  
Our previous data showed that Ab1-42 triggers rapid integrin-dependent adhesion 
and integrin activation in neutrophils through GPCRs, particularly through the 
fMLP receptor[65]. Therefore, we next investigated whether PAD inhibitors are able 
to block neutrophil adhesion triggered by oligomeric Ab1-42 in in vitro adhesion 
assays [65].  
Fig. 26. CXCR4, LFA-1 and VLA-4 protein expression levels are retained after PAD 
blocking.  
(a-c) Quantitative flow-cytometry analysis of a) CXCR4, b) LFA-1 b2 and c) VLA-4 b1 
integrin in human T lymphocyte following treatment with BB-Cl-amidine and GSK199 or 
not (ctrl). For all the surface molecule receptors, the graphs show the percentage of the 
fluorescence geometric mean (GEO MEAN) normalized to the control. Error bars represent 
SEM of 3 independent experiments. 
 
 




Our data show that, in static adhesion assays performed using both human and 
murine neutrophils, BB-Cl-amidine or GSK-199 treatment led to an impaired 
capability to bind b2 integrin ligand fibrinogen after Ab1-42 stimulus (Fig. 27), 
further confirming that PADs contribute to rapid integrin-dependent adhesion. BB-
Cl-amidine inhibitor performed better than GSK199, suggesting that both PAD 2 
and 4 control neutrophil adhesion in AD, potentially contributing to BBB damage 
and neuroinflammation in amyloid-rich areas.    
8. PAD INHIBITION IMPROVES MEMORY IN 3xTg-AD MICE 
Together, the results shown in this thesis demonstrate that PAD dependent 
citrullination is involved in leukocyte adhesion under physiopathological 
conditions. Indeed, pathological leukocyte recruitment plays a detrimental role in 
the pathogenesis of several inflammatory diseases[134]. Moreover, our previous 
a) 
b) 
Fig. 27. PAD blocking inhibits Ab-triggered neutrophil adhesion. 
(a-b) Static adhesion assays representing a) human and b) murine neutrophil adhesion to 
fibrinogen after BB-Cl-amidine and GSK199 treatments. Cells were incubated with 
indicated µM concentrations of drugs, or not (ctrl). After 30min of incubation, neutrophils 
were spotted on 12-well glass slides coated with human plasma fibrinogen and were 
stimulated with 5 µM of soluble oligomeric Ab1-42 for 1min. Adherent cell number is 
reported as mean values of 4 independent experiments; error bars represent SEM.  (* P < 





studies have shown that blood-derived infiltrating leukocytes are present in the 
brains of AD patients and corresponding animal models, promoting 
neuroinflammation and cognitive impairment[65].  
In order to evaluate the potential therapeutic effect of PADs inhibition in the context 
of AD, we performed in vivo experiments treating 3xTg-AD mice with BB-Cl-
amidine or GSK199. We first treated 6 month old 3xTg-AD for 4 weeks by 
intraperitoneal injection of BB-Cl-amidine. Then mice were tested for Y-maze 
spontaneous alternation task and contextual fear conditioning (CFC) tests. Potential 
motor dysfunctions were excluded through hindlimb clasping and ledge pre-
cognitive tests (data not shown). 
We performed Y-maze behavioural test in order to evaluate rodent short-term 
memory dependent on cortical functions and hippocampal spatial reference. Each 
mouse was placed in the central area of a symmetrical Y-maze apparatus and 
allowed to explore the three arms (A, B and C) of the maze for 8 min, recording 
total arm entries and alternation score (percentage of alternation). All groups (Fig. 
28a) showed comparable total number of arm entries, which indicated normal 
exploratory behaviour. As expected, PAD inhibition rescued 3xTg-AD spatial 
working memory to similar levels of sex- and age-matched wild type animals, 
whereas untreated 3xTg-AD displayed a decreased percentage of spontaneous 




The same groups of mice were then tested for CFC test, in order to evaluate rodent 
associative memory correlated with thalamus, hippocampus and sensory cortex 
activity. After a short training period, when animals learned to associate a foot 
shock with a 2Hz sound stimulus, we recorded the percentage of freezing behaviour 
(lack of movement), upon tone stimulation without the electric foot shock. In line 
with the results obtained in the Y-maze test, 3xTg-AD mice following treatment 
with the PAD inhibitor, showed improved fear learning response and memory, 
assuming similar wild type littermate behaviour (Fig. 28c). 
Collectively, these results indicated that the dysregulation of PADs plays a 
detrimental role in AD pathology, suggesting their inhibition as a new therapeutic 
strategy to ameliorate memory deficit and cognitive decline.  
a) b) 
c) 
Fig. 28. AD inhibition reverse memory impairment and cognitive decline in 3xTg-AD 
mice at 6 months of age. 
(a-c) 3xTg-AD and B6129SF2/J mice were treated with 10mg/kg BB-Cl-amidine or DMSO 
vehicle (control).   
(a-b) Mice were tested in Y-maze test at 8 months of age. (a) Total entries in the maze 
arms is reported; (b) the percentage of spontaneous alternation was calculated based on the 
entries into the three arms in overlapping triple sets (e.g., ABC but not ABA). 
c) Histograms showing the percentage of CFC freezing response during the sound 
stimulation, calculated by using ANY-maze software. 
Error bars represents mean ± SEM of one representative experiment with 15 mice per 







9. PAD INHIBITION REDUCES NEUROPATHOLOGICAL 
HALLMARKS OF AD 
We also performed immunohistological analysis of 3xTg-AD brains following BB-
Cl-amidine treatment in order to identify the neuropathological changes induced by 
PAD2 and PAD4 inhibition. We sacrificed the mice after behavioural tests, and we 
quantified three AD neuropathological markers, such as accumulation of Aβ, 
hyperphosphorylated form of tau protein, and microglial activation in cerebral 
cortex and hippocampus (CA1 and subiculum area).  
Fig. 29. PAD inhibition reduces amyloid accumulation in 3xTg-AD mice. 
(a-b) 6E10 monoclonal antibody staining representing Aβ accumulation in hippocampal 
CA1 region of 3xTg-AD mouse brain. 3xTg-AD following vehicle injection (DMSO), 
showed high intracellular levels of Aβ deposition, whereas BB-Cl-amidine treated mice 
are characterized by lower Aβ intracellular levels. a) Qualitative immunohistochemistry 
images. Higher magnification is reported in lower left panels. Scale bars, 50µm. b) 
Quantitative immunohistochemistry analysis. Aβ positive neuron area expressed as 
pixels2/total examined area. Values are expressed as mean ± SEM of 3 brains. (* P < 0.05; 






Fig. 29a shows a remarkable difference in hippocampal Aβ deposition between 
treated and untreated 3xTg-AD and these qualitative observations were confirmed 
by the quantitative analysis, which determined the total area occupied by Aβ- 
positive neurons. Indeed, the histograms from Fig. 29b show a significant decrease 
of amyloid area in 3xTg-AD after PAD inhibition compared to the tissues obtained 
from sex- and age-matched animals treated with vehicle. We also performed 
neuropathological studies on brain-resident microglial cells. As that these immune 
cells change their morphology and number when activated in response to 
neuroinflammatory stimuli, we quantified cell shape and density by performing 
immunohistochemistry in 3xTg-AD mice following BB-Cl-amidine treatment or 
vehicle administration.  
 As shown in Fig. 30a, our data revealed a smaller and thinner ramification of 
microglial cells in mice treated with PAD inhibitor compared to control 3xTg-AD, 
consistent with a significant reduction of  microgliosis. The quantitative analysis 
a) 
b) 
Fig. 30. PAD inhibition ameliorates microgliosis in 3xTg-AD mice. 
(a-b) Iba-1 monoclonal antibody staining showing microglial activation in hippocampus 
(CA1 and subiculum) and cerebral cortex of 3xTg-AD mouse brain. a) Qualitative 
immunohistochemistry results representing cortical morphological and numerical changes 
of microglial cells in 3xTg-AD following vehicle or BB-Cl-amidine injection. Higher 
magnification is reported in lower left panels. Scale bars, 25µm. b) Quantitative 
immunohistochemistry analysis performed in hippocampal regions (upper panels) and in 
cerebral cortex (lower panels). Microglial area is expressed as pixels2/total examined area, 
while density is reported as number of Iba-1 positive cells/total examined area. Values are 





confirmed a significant reduction in both cell area and density in hippocampus and 
cerebral cortex (Fig. 30b). 
Finally, we studied the effect of PAD inhibition on AD-related tau pathology 
through immunohistochemical analysis. We used an antibody that reacted with total 
tau protein and another which detected phosphorylated form of tau. Vehicle and 
BB-Cl-amidine treated mice showed comparable levels of hippocampal total tau 
protein, as illustrated in Fig. 31a. Notably, as shown in Fig. 31b-c, our data indicate 
a significant difference in hippocampal tau phosphorylation levels, which were 
lower in mice treated with PAD inhibitor compared to animals injected with 
vehicle.  
  
Collectively, our date indicate that PAD dysregulation has a detrimental role in AD, 
and that the therapeutic blockade of these enzymes reduces AD inflammatory 
Fig. 31. BB-Cl-amidine improves tau pathology in 3xTg-AD mice. 
a) Representative images of hippocampal CA1 region following staining with AT180 
antibody, detecting phosphorylated tau protein. Higher magnification is reported in lower 
panels. Scale bars, 50µm. b) Histograms showing comparable levels of total tau protein 
expression between vehicle and BB-Cl-amidine treated animals. c) Quantitative analysis of 
phosphorylated tau expressing cells in PAD inhibitor treated and control mice.  
(a, c) The area of total tau expressing cells is reported as pixel2/total examined area. Values 
are expressed as mean ± SEM of 3 immunohistochemical acquisitions. (* P < 0.05; Student’s 









events such as microglial activation, and mitigates neuropathological changes, 
including Aβ accumulation and tau protein phosphorylation. 
 
10. THERAPEUTIC PAD INHIBITION REDUCES LEUKOCYTE 
MIGRATION INTO THE BRAIN OF 3xTg-AD MICE 
AD animal models are characterized by infiltrating immune cells, adhering on brain 
vessels, and migrating into the parenchyma, where they contribute to disease 
pathogenesis, exacerbating neuroinflammation triggered by glial cells and Aβ 
accumulation and tau hyperphosphorylation.  We have shown above that PAD2 and 
PAD4 cooperated to mediate chemokine-induced integrin activation and 
consequent neutrophil and lymphocyte adhesion. In order to confirm the hypothesis 
that PAD2 and PAD4 control leukocyte trafficking in AD, which may explain the 
reduction of memory deficit and cognitive decline following pan PAD inhibition, 
we next quantified leukocyte subpopulations infiltrating 3xTg-AD mice brain after 
treatment with BB-Cl-amidine. As shown in Fig. 32, BB-Cl-amidine-injected mice 
exhibited lower cerebral accumulation of neutrophils, CD4+, and B lymphocytes, 
whereas PAD blockade seemed not to affect CD8+ and gd cell trafficking. 
However, the results were not statistically significant, very probably due to the 
small number of samples and to the high variability between animals. Additional 
studies need to be performed in order to confirm the positive correlation between 
PADs and leukocyte trafficking in the 3xTg-AD animal model. Even though not 
statistically significant, these results suggest that PAD inhibition leads to an 
amelioration of AD neuroinflammation and neuropathology by interfering with 
neutrophil and lymphocyte (CD4+ and B cells) extravasation. Interestingly, all 
these leukocyte subpopulations are able to release extracellular traps (ETs), which 
may induce tissue injury, suggesting a pathological link between leukocyte 




  Fig. 32. PAD inhibition reduces leukocyte migration into the brain of 3xTg-AD 
mice. 
Flow cytometry characterization of leukocyte (Ly6G+, CD4+, CD8+, gd+, B220+) 
subpopulations accumulated in the brains of 3xTg-AD mice following BB-Cl-amidine 
treatment or not (vehicle). The percentage of migrating cells was normalized to the 
total percentage of CD45high population. Data represent the mean ± SEM of at least 3 





PADs are a class of five Ca2+ dependent enzymes, which catalyses the 
posttranslational modification known as citrullination, where a positive arginine 
residue is converted into a neutral unconventional citrulline site. As a consequence 
of this reaction, the net protein charge in solution is modified, leading to a dramatic 
impact on the structure, conformation, and protein function, as well as intra or inter 
molecular interactions[135]. Citrullination represents a key regulatory element 
affecting several physiological cellular processes, such as gene expression, cell 
differentiation, apoptosis, and inflammatory immune responses.  
Among the PAD family, PAD2 and PAD4 isoforms have attracted more interest 
than the remaining members, considering their large detrimental role in a wide 
range of inflammatory and autoimmune diseases, tightly associated with the 
induction of leukocyte ET formation.  
ETosis is a recently described cell death associated phenomenon that results in the 
release of chromatin web-like structures equipped with citrullinated histones and 
granule-associated proteins that entrap and kill pathological microorganisms.  
Initially, this phenomenon was described to occur only in neutrophils. However, 
recent studies have demonstrated that other cell types, such as macrophages, CD4+, 
and B lymphocytes contribute to this host defense mechanism by releasing traps 
similar to those identified in neutrophils[136].  
During ETosis, several inflammatory stimuli, such as bacteria, virus, LPS, or IFN 
a/g, activate the NADPH oxidase complex, leading to ROS production and 
consequently an increase in free intracellular Ca2+ levels. Since PAD activity is 
strictly dependent on Ca2+ influx, once it rises, PAD2 and PAD4 became activated 
and translocate to the nucleus where they target H3 and H4 histones, and H2A tails. 
The resulting loss in electrostatic attractions between negative DNA and neutral 
citrullinated histones leads to extensive chromatin decondensation, and the 
downstream signalling pathways end with the release of ETs[137].  
A dysregulation in ET release or clearance is toxic and immunogenic, and it is 
correlated with RA, SLE, atherosclerosis, and UC[138], all pathologies in which 




onset and progression. Pharmacological interventions, which selectively block 
PAD-mediated citrullination, are considered a novel therapeutic strategy for the 
mentioned pathologies.  
Treatment of atherosclerosis murine models with Cl-amidine, a pan PAD inhibitor, 
reduces atherosclerosis burden, arterial thrombosis, and recruitment of netting 
neutrophils and macrophages to the inflamed arteries[78]. Murine models of SLE are 
protected from lupus-related vascular and skin damage since they present less 
immune complex deposition and leukocyte migration to the kidneys after PAD 
inhibition[106]. Moreover, RA animal models, treated with BB-Cl-amidine, rescue 
the severity of clinical disease activity, and mitigate the intense inflammatory cell 
infiltration to the synovial joints[98]. In UC, pan-PAD inhibition has shown 
efficiency in reducing clinical signs and symptoms, attenuating colon inflammation 
associated with aberrant leukocyte infiltration into injured intestinal tissue[103]. All 
these results suggest that PAD blocking drugs result in an amelioration of general 
inflammation state, strictly correlated with a reduction of immune cell infiltration 
to the inflamed zone.  
Previous studies have shown that leukocyte recruitment may be mitigated as a 
consequence of in vivo PAD inhibition but whether PADs directly control immune 
cell adhesion in the context of inflammation has not yet been investigated. 
Ca2+ signalling plays a crucial role during leukocyte migration since it is spatially 
and temporally released from ER stores to coordinate rolling, arrest, and cell 
polarization events[139]. The fact that PAD catalytic activity is strictly dependent on 
Ca2+ influx, which is increased in immune cell trafficking events, is in line with a 
potential physiological involvement of citrullination in leukocyte adhesion cascade.  
Several proinflammatory NET inducers are also able to mediate leukocyte firm 
adhesion arrest, suggesting that PADs may indeed play a role in immune cell 
trafficking. Phorbol myristate acetate (PMA) stimulates DNA release through the 
activation of protein kinase C (PKC), an upstream mediator of NADPH, and 
promotes LFA-1 dependent adhesion[140, 141]. fMLP is one of the most physiological 
NET inducers and mediates G-protein coupled receptor intracellular signalling 
leading to neutrophil firm adhesion[24, 142]. Inflammatory cytokines, such as 




neutrophil adhesion[143-145]. Therefore, in the present thesis we investigation a 
potential PAD role in the adhesive activity of leukocytes under physiological and 
pathological conditions. 
The results obtained demonstrate that PAD blocking induces a statistically 
significant decrease of neutrophil and lymphocyte integrin-dependent rapid 
adhesion, using both humans and mouse cells. Also, our data show that leukocyte 
adhesiveness via b2 (LFA-1 and MAC1) and b1 (VLA-4) integrins is blocked  after 
PAD inhibition, suggesting that integrins are transmembrane receptors sharing the 
same citrullination targets. Our data are also supported by the genetical approach 
of PAD2 silencing mediated by siRNAs, which confirmed PAD2 and PAD4 
contribution to LFA-1-triggered adhesion. It also demonstrated that these isoforms 
cooperate to induce ICAM-1 binding, previously shown by pan PAD inhibitor BB-
Cl-amidine. This result is not totally unexpected, considering that PAD2 has in 
common some citrullinated targets with PAD4, such as histones[24]. Based on our 
data, it is difficult to clearly establish whether the cooperation between the two 
enzymes is due to additive or synergistic enzyme interactions since we did not 
determine the contribution of PAD4 specific siRNA silencing. However, the 
synergy between PAD2 and PAD4 was recently demonstrated in macrophages[146] 
in which pan PAD blockage showed that the sum of the single isoform-blocking 
drugs greater inhibited NLRP3 inflammasome assembly and IL-1b released. 
Therefore, we speculate that, in our adhesion assays, both PAD2 and PAD4 
participate in LFA-1 integrin-mediated firm adhesion. However, GSK199 
treatment inhibited leukocyte adhesion on VCAM-1 only at the highest 
concentration, and when it was combined with PAD2 siRNAs, there was no further 
reduction in the adhesion, suggesting that PAD2 citrullinates additional targets 
implicated in b1 integrin-dependent adhesion that are not in common with PAD4. 
Indeed, in support of this hypothesis, previous data showed that among 159 selected 
PAD4 substrates, only 18 are shared with PAD2[147]. 
In this thesis we have also studied the mechanism behind the role of PADs in 
leukocyte adhesion, showing for the first time that citrullination regulates the 
complex inside-out signalling pathways leading to integrin activation. We 




affinity to the extended intermediate conformation, preventing the opening of the 
ICAM-1 binding pocket. We focused our attention only on LFA-1 since it is the 
best-characterized integrin in terms of structural rearrangements and since both 
PAD2 and PAD4 showed to affect leukocyte adhesion on ICAM-1 ligand. At least 
50 proteins have been implicated in the regulation of integrin-mediated adhesion, 
resulting in a network of more than 6000 protein-protein interactions[108]. Therefore, 
finding the exact collocation of PADs in this enormous complexity, not yet fully 
understood, represents a difficult challenge. Considering that RG/RGG motif has 
been recently described as a consensus sequence for PAD4-mediated 
citrullination[147], we speculate that LFA-1 itself might be the citrullinated substrate 
since its b tail subdomain contains this consensus motif (Fig. 33). 
Several cytoskeletal proteins are counted among the PAD substrates, such as a 
actinin, actin, vimentin, fibronectin, tubulin, and filaggrin[148]. L-selectin binds 
actin through a membrane distal binding site for α-actinin and a membrane-
proximal binding site for ezrin/radixin/moesin (ERM) proteins, a family composed 
of cytoplasmic proteins with the capability to bind simultaneously actin and the 
cytoplasmic tails of different transmembrane proteins[149]. These interactions 
provide a direct cytoskeletal anchorage, which is essential for supporting leukocyte 
Fig. 33. Fasta sequence of human ITB2 (P05107 UniProtKB) 
The amino acid sequence of b2 subunit integrin is represented. PAD consensus sequence 
is evidenced in red and it is collocated at 593-594 positions. 
Information available at: https://www.uniprot.org/uniprot/P05107 
MLGLRPPLLA LVGLLSLGCV LSQECTKFKV SSCRECIESG PGCTWCQKLN  
        60         70         80         90        100 
FTGPGDPDSI RCDTRPQLLM RGCAADDIMD PTSLAETQED HNGGQKQLSP  
       110        120        130        140        150 
QKVTLYLRPG QAAAFNVTFR RAKGYPIDLY YLMDLSYSML DDLRNVKKLG  
       160        170        180        190        200 
GDLLRALNEI TESGRIGFGS FVDKTVLPFV NTHPDKLRNP CPNKEKECQP  
       210        220        230        240        250 
PFAFRHVLKL TNNSNQFQTE VGKQLISGNL DAPEGGLDAM MQVAACPEEI  
       260        270        280        290        300 
GWRNVTRLLV FATDDGFHFA GDGKLGAILT PNDGRCHLED NLYKRSNEFD  
       310        320        330        340        350 
YPSVGQLAHK LAENNIQPIF AVTSRMVKTY EKLTEIIPKS AVGELSEDSS  
       360        370        380        390        400 
NVVQLIKNAY NKLSSRVFLD HNALPDTLKV TYDSFCSNGV THRNQPRGDC  
       410        420        430        440        450 
DGVQINVPIT FQVKVTATEC IQEQSFVIRA LGFTDIVTVQ VLPQCECRCR  
       460        470        480        490        500 
DQSRDRSLCH GKGFLECGIC RCDTGYIGKN CECQTQGRSS QELEGSCRKD  
       510        520        530        540        550 
NNSIICSGLG DCVCGQCLCH TSDVPGKLIY GQYCECDTIN CERYNGQVCG  
       560        570        580        590        600 
GPGRGLCFCG KCRCHPGFEG SACQCERTTE GCLNPRRVEC SGRGRCRCNV  
       610        620        630        640        650 
CECHSGYQLP LCQECPGCPS PCGKYISCAE CLKFEKGPFG KNCSAACPGL  
       660        670        680        690        700 
QLSNNPVKGR TCKERDSEGC WVAYTLEQQD GMDRYLIYVD ESRECVAGPN  
       710        720        730        740        750 
IAAIVGGTVA GIVLIGILLL VIWKALIHLS DLREYRRFEK EKLKSQWNND  
       760  





rolling. Considering that citrullination affects protein-protein interactions and that 
some of these cytoskeletal proteins, such as actin and α-actinin, are well-known 
targets of PAD2 and PAD4, we cannot exclude the possibility that PADs could be 
involved not only in firm arrest but also in rolling interactions.  
The impact of all these findings in biomedicine is relevant, providing a novel 
therapeutic strategy against all the inflammatory diseases in which leukocyte 
recruitment plays a critical role in disease pathogenesis. Recently, our group has 
demonstrated that unwanted leukocyte transmigration characterizes AD, where 
leukocyte infiltration occurs through a dysfunctional BBB) and contributes to 
disease pathogenesis[65]. CD4+ and CD8+ T cells were found to adhere to the 
vascular endothelium of AD patients and animal models, as well as neutrophils, 
which release IL-17 and NETs, contributing to AD cognitive impairment. We also 
previously discovered that LFA-1 integrin is the main adhesion molecule mediating 
intravascular cell adhesion in AD mouse models[65]. Based on these data, in this 
thesis we translated to the AD pathological context what we found under in vitro 
conditions. Importantly, the comparison of human and murine data revealed that 
the inhibitory effect is preserved in cells of both species, even though the drugs 
performed slightly better in human than in mouse leukocytes. Moreover, it was 
previously suggested that PADs are involved in AD pathogenesis since their 
upregulation has been already observed in the hippocampus of AD patients, where 
citrullinated proteins are also detected. We here showed that the pathological Ab1-
42-triggered neutrophil adhesion is dependent on PAD citrullination, clearly 
indicating a role for PADs in AD. Furthermore, we discovered that PAD blocking 
might be considered a novel therapy in AD since BB-Cl-amidine treatment reversed 
memory impairment, cognitive dysfunction, and neuropathological changes in 
3xTg-AD mice.  
The mechanism by which PAD inhibition leads to an amelioration of AD 
neuroinflammation may be due to the inhibition of the extravasation of neutrophils, 
CD4+, and B cells, whereas PAD blocking seemed not to affect CD8+ and gd T cell 
trafficking. A different CD4+ and CD8+ adhesive behavior has already been 
demonstrated in chronic brain inflammation. For instance,  the study of the 




mucin PSGL-1 was critical for CD8+ lymphocyte migration into inflamed brain 
vessels, whereas rolling and adhesion of CD4+ cells were strictly controlled by 
VLA-4 in experimental conditions with relevance to MS[150]. We confirmed this 
CD4+/CD8+ dichotomy in the brain of 3xTg-AD mouse models, where CD4+ T cells 
seemed to be dependent on a4 integrins for cell extravasation[113]. It is important to 
underline that PAD inhibition of restricted T subsets should be considered 
preliminary findings since these results were not statistically significant, probably 
due to the small number of samples and the high variability between animals. 
Therefore, future experiments are needed to conclude that PADs mediate the 
recruitment of neutrophils, CD4+, and B cells in AD mouse models. Even if it is just 
a pilot discovery, we can speculate that the only affected leukocyte subpopulations 
by PAD inhibition are those able to release ETs. Apart from the well-documented 
NETs, recently, B lymphocytes have been shown to release extracellularly 
interferogenic DNA webs in vitro as a rapid antiviral messenger molecule, although 
it is still unclear if this process may occur in vivo[151]. More recently, it has been 
found that even activated CD4+ T cells eject DNA extrusions, called T helper-
released extracellular DNA (THRED)[28]. The association between neutrophil 
trafficking and NETs has been well established in a wide range of NET driven 
diseases, known as NETophaties, where clinical and experimental data indicate that 
circulating neutrophils are recruited to the site of infection or inflammation through 
adhesive endothelial interactions, resulting in rapid cell infiltration and NETosis, in 
addition to the canonical phagocytosis and degranulation[152]. This mechanism has 
also been demonstrated in AD, where our group demonstrated the detrimental role 
of neutrophils in transgenic mice with AD-like pathology, partly related to NET 
release inside the blood vessels and parenchyma[66].  
In conclusion, the results shown in this thesis suggest a pathological role for PADs, 
which may catalyze citrullination of substrates involved in integrin activation and 
subsequent adhesion, potentially exacerbating neuroinflammation and CNS 
damage. Our data also suggest that interfering with PAD activity may represent a 
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